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INVESTIGATING THE ROLE OF EXOSOMAL COMMUNICATION
WITHIN THE GLIOMA MICROENVIRONMENT

Javier Miguel Figueroa II, M.S.Supervisory Professor: Frederick F. Lang, M.D.

Evidence indicates that human cancers are maintained by a population of
cells with stem-like properties called cancer stem cells (CSCs). However, the
influence of the surrounding stromal cells on the behavior of the CSCs remains
poorly understood. We have recently shown that the micro-environment of human
gliomas, the most aggressive human brain tumors, contains both glioma stem cells
(GSCs) and cells that resemble human bone marrow-derived mesenchymal stem
cells (BM-MSCs), called Glioma Associated-MSCs (GA-MSCs). We have also
shown that GA-MSCs generate a cytokine-mediated increase in the growth and selfrenewal (clonogenicity) of GSCs. However, other paracrine interactions between
GA-MSCs and GSCs have not been fully explored. Recent studies have suggested
that nano-sized vesicles, termed exosomes, may contribute to intercellular
communication within the tumor niche. Therefore, I hypothesized that GA-MSCderived exosomesincrease the growth and evolution of gliomas. Here I show for the
first time that exosomes can be isolated from patient-derived GA-MSCs and that
these exosomes contain oncogenic microRNAs. Importantly, in vitro delivery of
exosomes isolated from GA-MSCs significantly increased both the proliferation and
clonogenicity of GSCs. Furthermore, GSC xenografts,treated with GA-MSC-derived
exosomes, inthe brains of nude mice resulted in a greater tumor burden and
significantly decreased animal survival. Lastly, delivery of microRNA identified as
both highly expressed and highly enriched in GA-MSC-derived exosomes, altered
gene expression in recipient GSCs resulting in the glioma-enhancing effects
described. I conclude that GA-MSC-derived exosomes represent an alternative
intercellular communication mechanism for the transfer of specific microRNAs, which
enhance the aggressive nature of Gliomas.

vi

Table of Contents

Approval Signatures ……………………………………………………..……………… i
Title Page ……………………………………………………………………..…………. ii
Copyright ……………………………………………………………………...…………. iii
Dedication ………………………………………………………………..…………….... iv
Acknowledgements …………………………………………..…………………………. v
Abstract …………………………………………………………………...……….......... vi
Table of Contents ………………………………………………………...…………….. vii
List of Figures ………………………………………………………………………….... ix
List of Tables …………………………………………………………………………….. xii
Abbreviations ……………………………………………………………………………. xiii
Chapter 1 Introduction …………………….……………………………..……………... 1
1.1 Exosome Background ………….………………………………………… 3
1.2 Gliomas and Exosomes ………………………………………………….. 11
1.3 The Glioma Microenvironment…………………………..………………... 16
1.4 Glioma Associated Mesenchymal Stem Cells …………………….......

24

1.5 The Role of MSCs in the Tumor Niche …….……………………………...32
1.6 Conclusion……………………………………………………………………. 41
1.7 Hypothesis……………………………………………………………………. 42

vii

Chapter 2 Isolation and Characterization of GA-MSC-Derived Exosomes .............43
2.1 Experimental Methods …………………………………………………….. 45
2.2 Results ……………………………………………………………………….. 51
2.3 Discussion …………………………………………………………… ……... 73
2.4 Conclusions …………………………………………………………………..78
Chapter 3 GA-MSC-Derived Exosomes Increase GSC Tumorigenicity ………….. 79
3.1 Experimental Methods ……………………………………………………... 81
3.2 Results ……………………………………………………………………….. 84
3.3 Discussion …………………………………………………………………...101
3.4 Conclusions ………………………………………………………………….105
Chapter 4 MicroRNA in GA-MSC-Derived Exosomes Promote Glioma Growth....106
4.1 Experimental Methods ……………………………………………………...108
4.2 Results……………………………………………………………………….114
4.3 Discussion …………………………………………………………………...138
4.4 Conclusions ………………………………………………………………….145
Chapter 5 Research Summary……………..………….……………………………….146
5.1 Experimental Conclusions …………………………………………………148
5.2 Research Significance ……………………………………………………..149
5.3 Future Investigations ……………………………………………………….150
References ………………..………………………………………………...…………...151
Vita …………………..……………………………………………………………...........181

viii

List of Figures

1.

Exosomes are formed by an intracellular process....................................... 5

2.

Exosome contain cellular elements………………………...…………………. 8

3.

Exosomes can be taken up by target cells………………………………...…. 10

4.

GSC exhibit specific morphology in cell culture………………………...….… 18

5.

GSCs express a glial stem cell marker………………………………...……... 19

6.

GSCs are tumorigenic…………………………………………………..……… 20

7.

GSCs harbor known mutations of gliomas…………………………..………. 21

8.

GA-MSCs exhibit specific morphology in cell culture……………..………… 27

9.

GA-MSCs express known MSC markers…………………………..………… 28

10.

GA-MSCs can tri-differentiate along mesenchymal lines……………..……. 29

11.

Matching GSCs and GA-MSCs do not
harbor the same genetic mutations.............................................................. 30

12.

GA-MSCs are not tumorigenic……………………………………………..….. 31

13.

GA-MSCs promote the growth and self-renewal of GSCs……………..…... 33

14.

GA-MSCs decrease median survival in mice with GSC xenografts…..…... 34

15.

GA-MSCs increase tumor burden in mice with GSC xenografts……..……. 35

16.

GA-MSCs secrete growth promoting cytokines…………………………...…. 36

17.

IL-6 secretion from GA-MSCs activates STAT3………………………...…… 37

18.

MSC-derived nano-vesicles express exosomal markers……………..……. 52

ix

19.

Morphology of MSC-derived nano-vesicles is identical to exosomes .…..… 53

20.

Exosome marker is expressed on MSC-derived nano-vesicles ...……..….. 54

21.

MSC-derived nano-vesicles exhibit exosome size distribution………..…… 56

22.

MSC-derived exosomes exhibit specific production systems………..…….. 57

23.

MSC-derived exosomes do not contain growth factors………………...…… 62

24.

MSC-derived exosomes do not contain cytokines……………………..……. 64

25.

MSC-derived exosomes contain miRNA…………………………………..…. 66

26.

MicroRNA profiles of MSC-derived exosomes are different……………...… 71

27.

GSCs internalize fluorescently labeled MSC-derived exosomes ………..… 85

28.

GA-MSC-derived exosomes increase GSC proliferation………………..…. 86

29.

GA-MSC-derived exosomes increase GSC clonogenicity………………..... 91

30.

GA-MSC-derived exosomes decrease median survival………………..…... 96

31.

GA-MSC-derived exosomes increase tumor burden (20 days)……………. 97

32.

GA-MSC-derived exosomes increase tumor burden (40 days)……………. 99

33.

GA-MSC-derived exosomes contain highly
expressedand highly enriched miRNA……………………………………….116

34.

Predicted gene targets of exosome enriched miRNA are downregulated aftertreatment of GSCs with GA-MSC-derived exosomes……..123

35.

Lentiviral transduction of miRNA constructs
increases expression in GSCs………………………………………………....125

36.

Over-expression of specific exosome enriched
miRNA increases proliferation in GSCs……………………………………....131

x

37.

Over-expression of miR-1587 in GSCs increases proliferation…………....132

38.

Over-expression of specific exosome enriched
miRNA in GSCs increases clonogenicity……………………………………..134

39.

Over-expression of miR-1587 in GSCs increases clonogenicity…………..135

40.

NCOR1 is down-regulated in GSCs over-expressing miR-1587…………..137

xi

List of Tables

1.

GA-MSCs exhibit MSC-like characteristics….………………………………..46

2.

GSCs exhibit CSC-like characteristics………..………………………………. 47

3.

MSC-derive exosomes do not contain major growth factors …….....……… 60

4.

MSC-derive exosomes do not contain major cytokines…………………….. 63

5.

MSC-derived exosomes contain highly expressed miRNA………..……….. 72

6.

MSC-derived exosomes contain highly enriched miRNA………………......115

7.

MSC-derived exosomes contain enriched and depleted miRNA…..……...117

8.

Exosomal miRNAs have varying nucleotide ratios..………………………...118

9.

Exosomal miRNA contain specific nucleotide sequences..………………...120

10.

MicroRNAs enriched in GA-MSC-derived exosomes downregulate predicted gene targets in GSCs...…………………………...……122

xii

Abbreviations

BM-MSC: Bone Marrow-Mesenchymal Stem Cell
CAF: Cancer Associated Fibroblast
CD: Cluster of Differentiation
CM: Conditioned Medium
CSC: Cancer Stem Cell
EF-CM: Exosomes-Free Conditioned Medium
EM: Electron Microscopy
ESCRT: Endosomal Sorting Complex Required for Transport
GA-MSC: Glioma Associated-Mesenchymal Stem Cell
GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase
GBM: Glioblastoma Multiforme
GSC: Glioma Stem Cell
ISCT: International Society for Cellular Therapy
LV: Lentiviral
mRNA: Messenger-Ribonucleic Acid
miRNA: Micro-Ribonucleic Acid
MSC: Mesenchymal Stem Cell
MVB: Multivesicular Body
NCOR1: Nuclear Receptor Corepressor-1
NSC: Neural Stem Cell
RISC: Ribonucleic Acid-Induced Silencing Complex
TA-MSC: Tumor Associated-Mesenchymal Stem Cell
TMZ: Temozolomide
xiii

Chapter 1
Introduction

Introduction

Breakthroughs in biological science are typically the result of cutting-edge
research exploring novel mechanisms of physiologic and pathologic processes. For
intercellular communication, the forefront of present research has recently shifted
from protein signal transduction to exosomal paracrine mechanisms. For cancer, the
vanguard of current research has moved from the study of tumor propagating cells
to the investigation of the complex interactions within the tumor micro-environment.
These front lines of discovery converge in an area evaluating the exosomal
paracrine intercellular signaling within the microenvironment of tumors. Considering
the variety of possible exosomal contents, the crosstalk between tumor propagating
cells and the surrounding tumor niche via the transfer of exosomes is likely
paramount to that of protein receptor activation. Therefore, my research investigates
the role of exosomal communication within the micro-environment of tumors.
Specifically, I focused my studies on the interaction between glioma stroma-derived
exosomes and glioma propagating cells, and the resulting effects of this
communication pathway. This subject has never been studied in gliomas, and
significant findings will establish a novel mechanism for communication within the
tumor micro-environment, as well as a potential target for adjunct therapy. Given the
complexity of cancer, the success of future curative therapies relies on a full
understanding of tumor biology that includes evaluation of the intercellular exosomal
communication system within the tumor microenvironment.
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1.1 Exosome Background
Intercellular communication has previously been characterized as the transfer
of ions, proteins, hormones, and lipids.1-4 However, evidence for an alternative form
of communication between neighboring cells, involving the delivery of proteomic and
genetic elements via exosomes, is building. Exosomes are quickly being recognized
as an important part of cell biology in both physiologic and pathologic conditions.5-9
Therefore, in cancer research, it is essential that we evaluate this mechanism of cellto-cell interaction in order to move towards a more complete understanding of the
microenvironment in which a tumor forms and progresses.
The term exosome is used to specify a subset of small microvesicles, and is
not to be confused with the unrelated intracellular RNA degrading exosomecomplex.10-11 Exosomes belong to a class of extracellular vesicles, and are the
smallest in the group. An exosome is a 40-100 nm diameter particle composed of
the same lipid bi-layer membrane from the originating cell.12 Thus the size of
exosomes limits their analysis by light microscopy, which has a lower limit of
approximately 200nm, and instead requires the utilization of electron microscopy. 13
Conversely, light microscopy can be used to observe larger extracellular vesicles,
specifically microvesicles (200-1000nm in diameter) and apoptotic bodies (1-5µm in
diameter).13 Exosomes are also found to have a density range of 1.10-1.19 g/mL,
which differs from that of heavier microvesicles (1.17-1.25 g/mL) and apoptotic
bodies (1.24-1.28 g/mL).13 The formation of exosomes takes place intracellularly
within the endosomal/lysosomal system, after which they are excreted from the cell
via exocytosis. This process also distinguishes exosomes from larger microvesicles
and apoptotic bodies, which form by external membrane budding or blebbing, and
fragmentation of the plasma membrane, respectively.14
Exosomes were first described via electron microscopy (EM) in 1981 by
Trams, et al, as a smaller subset of a group of larger microvesicles derived from the
C-6 rat glioma cell line.15 Here, the authors were investigating the ecto-5’nucleotidase activity of a group of large microvesicles (500-1000nm in diameter) that
budded from the plasma membrane of glioma cells. Their EM analysis however,
3

demonstrated the presence of a smaller subset of microvesicles (40-100nm in
diameter) that had no ecto-5’-nucleotidase activity and did not seem to form from
plasma membrane blebbing. Trams and colleagues were the first to propose the
term exosomes for the nano-sized vesicles.15 Subsequently in 1983, Pan, et al,
described a physiologic role for exosomes in the elimination of the transferrin
receptor during reticulocyte maturation.16 Here, investigators found that mature
sheep reticulocytes no longer required transferrin receptors to maintain intracellular
iron homeostasis. Unutilized receptors were then recycled to endosomal
compartments within the cell, and then excreted into the extracellular space in
exosomes.16 These two seminal papers revealed exosomes to be a novel part of cell
biology, and since that time the literature on exosomes has increased exponentially.
An important part of studying exosomes is understanding how they are
formed. This knowledge could lead to more accurate detailing of their composition,
and help determine their function. Exosomes form within the endosomal system.
This system is responsible for intracellular protein trafficking between various
organelles and the cell membrane. The formation of exosomes initially involves the
recycling of plasma membrane receptors and proteins, via clathrin-associated
endocytosis, resulting in the extracellular domain of membrane proteins now within
the intra-endosomal compartment. This process signifies the creation of the early
endosomes in the cytosol (Figure 1).17 Early endosomes then follow one of two
pathways, depending on their content and function. The first pathway involves fusion
with a lysosome, resulting in degradation and recycling of intra-endosomal
contents.17 The second pathway involves lysosomal escape which is thought to be
signaled by specific endosomal membrane components. Lysosomal escape results
in the eventual maturation of early endosomes into late endosomes.17 The
membrane of late endosomes then undergoes the process of reverse endosomal
budding, which is essentially endocytosis of the endosomal membrane. This process
forms smaller vesicles within the endosome, which now have the extracellular
domain of recycled plasma membrane proteins in the extra-vesicular compartment.
The formation of these intra-endosomal vesicles, which are future exosomes,
signifies the creation of the multi-vesicular body (MVB).17 MVBs then traffic their
4

Figure 1. Exosomes are formed by an intracellular
process. (1) Clathrin-coated pit endocytosis, recycling
plasma membrane components. (2) Formation of an
early endosomes that escape lysosomal degradation,
becoming a late endosome. (3) Reverse-inward
budding resulting in exosomes within intra-endosomal
compartment, and forming a multi-vesicular body
(MVB). (4) Fusion of the MVB membrane with the
plasma membrane, releasing exosomes into the
17
extracellular space.
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cargo of exosomes through the cytoplasm to the plasma membrane.17 Fusion of
MVBs with the cell membrane occurs in an energy-dependent, calcium-mediated,
process.18-19 This process is similar to the mechanism used by neurons to release
pre-packaged neurotransmitter vesicles from the axon terminal into the synaptic
space. After the MVB fuses with the plasma membrane, the exosomes are released
with similar, but not identical, membrane receptors and proteins characteristic of the
originating cell. Once in the extracellular milieu, exosomes are able to bind to target
cells and complete the intercellular interaction by transferring their internal cargo.17
One key aspect of exosome formation that is poorly understood is the
concentrating and packaging of specific cellular elements in the exosomal
membrane and inside exosomes. The composition of the exosomal membrane is not
identical to that of the cell membrane from which it was derived. Although the two
membranes are similar to each other, exosomal membranes lack many of the
common cluster of differentiation (CD) and fragment crystallizable (Fc) surface
proteins, as well as various integrins, that are present on the plasma membrane.20
Thus, the components of the membrane are altered during protein recycling and
exosome

formation,

concentrated.

20

with

certain

lipids

and

proteins

being

removed

or

For instance, compared to the cell of origin, exosomes have an

increased concentration of ceramide, an important lipid membrane constituent
capable of cellular signaling.21 This indicates that the composition of the exosome
membrane is distinctive and purposeful, and is not indiscriminately compiled.
Similarly, the intra-exosomal content is comparable, but not identical, to that of the
parental cell.22 The packaging of cellular elements into exosomes has been linked to
the ESCRT (endosomal sorting complex required for transport) machinery, which is
part of the endosomal system and responsible for trafficking of proteins and
remodeling of cellular membranes during exosome formation. 23 Variations in this
process can lead to either enrichment or depletion of exosomal content depending
on the needs of the cell.22 For instance, specific nucleotide motifs on RNA molecules
can be recognized by ribonucleoproteins (RNPs), which lead to the cell preferentially
packaging messenger-RNA (mRNA) or microRNA (miRNA) into exosomes.24-26 The
unique differences between the composition of exosomes and the cell of origin
6

indicate that exosome formation is not a random process, and that both the
membrane constituents and intra-exosomal content are assembled for a distinct
purpose in cellular biology.
Exosomes are known to contain a wide variety of cellular elements that are in
the exosomal membrane (Figure 2).27 Likewise, the function of these membrane
constituents is broad. Evidence shows that exosome membrane can contain
integrins, which can mediate binding in the extracellular space and may play a role
in internalization by a recipient cell.28-29 Additionally, studies show that the
membranes of exosomes can contain major histocompatibility complexes (MHC)
which can participate in antigen presentation and immune responses to infection and
cancer.30-31 Many other membrane proteins have been described in exosomes,
some of which have no known or accepted function at this time. Specifically, proteins
in the tetraspanin family, which are thought to be membrane scaffold proteins, have
been ubiquitously described in exosomes. However, the role of these proteins in
exosomes is still under investigation. Included in the tetraspanin family are various
cluster of differentiation proteins, including CD9, CD37, CD63, and CD81, which are
all used as surface markers for exosomes.32-33 CD63 is one of the most utilized
tetraspanin surface markers in exosomes from a variety of cell types, and has been
linked to antigen presentation via association with MHC molecules.34 This
assortment of proteins represents only a fraction of the exosomal membrane
constituents, and new functional components are still being discovered.
Similar to the exosomal membrane components, the intra-exosomal
compartment is home to a wide variety of cellular elements (Figure 2).27 However
unlike the membrane components, the roles of nearly all cellular elements within
exosomes are well known. The glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is known to play a major role in intracellular vesicular
trafficking, and may also indicate a metabolic role for exosomes.35-36 The intraexosomal compartment can also contain functional genetic elements, not present in
exosomal membranes. The transfer of mRNA via exosomes has been described in a
variety of disease processes, including cancer. Once inside the recipient cell,
7

Figure 2. Exosome contain cellular elements. The
exosomal membrane contains a variety of proteins, including
the family of tetraspanins used as exosomal markers. The
intra-exosomal compartment contains various cellular
27
elements, including soluble proteins (GAPDH) and RNA.
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exosome-delivered mRNA can be translated by recipient cell machinery. Evidence
shows that oncogenic mRNA within exosomes can enhance gene expression in noncancer cells, thereby modifying cellular biology.37-38 Additionally, miRNA have been
extensively described in exosomes from numerous cell types. Once in the cytoplasm
of the recipient cell, miRNA can regulate gene expression by binding to
complementary regions in the 3-prime untranslated region (3’UTR) of mRNA, and
inhibiting translation. Studies show that the exosome-mediated transfer of oncogenic
miRNAs can alter the biology of non-cancer cells, while the transfer of tumorsuppressor miRNAs can inhibit tumor growth.39-42 Importantly, exosome profiling has
drastically expanded the list of known contents, which adds to the complexity of this
intercellular communication system.
Interaction of exosomes with recipient cells has been shown to occur in two
distinct forms, both of which are receptor mediated: direct fusion or endocytic
internalization (Figure 3).43 The exosomal membrane constituents include proteins
that can serve to target exosomes to specific recipient cells. For example, exosomes
from platelets readily bind to endothelial cells and macrophages, but not to
neutrophils.44 This highlights the complexity of exosome function, and suggests that
they are not universally taken up by all cell types. Thus, targeting of exosomes to a
specific destination must be encoded into the exosomal membrane for recognition
by a specific recipient cell type. Upon receptor interaction with the desired cell,
exosomes can either fuse with plasma membrane or be internalized by
endocytosis.45-46 Either pathway will eventually result in transfer of receptors to the
cell plasma membrane, as well as the transmission of exosome contents, including
RNA, into the cytosol.43 In the case of immediate fusion with the plasma membrane,
the contents of the exosomes can readily interact with their cytosolic targets, for
instance miRNA can begin to bind and inhibit mRNA gene transcripts. 27 However,
the fate of exosomes which undergo endocytosis is variable, with some exposed to
lysosomal degradation or recycling to the extracellular space.17 Only exosomes
which escape these degradative processes and release their content into the
recipient cell cytoplasm, will have successfully navigated the entire exosomal
intercellular communication pathway, to induce a targeted effect.
9

Figure 3. Exosomes can be taken up by target
cells. (1) Exosome can bind receptors on the
plasma membrane of the recipient cell, and
initiate endocytosis for internalization into the
cytoplasm. (2) Exosomes can fusion with the
plasma membrane of the recipient cell, releasing
43
their contents into the cytoplasm.
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1.2 Gliomas and Exosomes
Exosomes were first described in the setting of cancer, therefore it is fitting
that the majority of research since that time has been devoted to exploring their role
in malignancy.15 To date, exosomes have been described in a wide variety of cancer
types and in numerous aspect of tumor biology, from promoting metastases and
malignant progression, to utilizations as diagnostic/prognostic markers, and as novel
delivery vehicles for therapeutics.47-53 Furthermore, exosomes have been implicated
in

modulation

of

the

immune

response

to

tumors,

subjugation

of

the

microenvironment, and resistance to chemotherapy.54-59 Exosomes derived from
lung, breast and prostate cancers are the most widely studied.60-62 However, with
respect to gliomas, the evidence for exosome interactions within malignancies of the
brain is less extensive.63-65 Nevertheless, the unique anatomical nature and isolated
environment of the brain only add to the potential for significant exosomal function in
localized tumors.
At present time, there are a limited number of published studies pertaining to
human gliomas and exosomes. These few reports can be grouped into three broad
categories; reviews, basic science, and translational. The reviews sought to
correlate the knowledge of exosomes from research areas outside the central
nervous system, to that of gliomas.63-65 The review published by van der Vos, et al.,
focused on the changes mediated by transfer of exosomal RNA in the glioma
microenvironment, as well as the utilization of exosomes as a diagnostic
biomarker.63 A subsequent review by, D’asti and colleagues, addressed the
biogenesis and characterization of exosomes in glioma, as well as the oncogenic
potential of the exosomal cargo.64 The latest review, by Gonda, et al., concentrated
on the modulation of the tumor microenvironment by exosomes in glioma, as well as
the therapeutic applications for exosomes against gliomas. 65 These comprehensive
reviews cover much of the currently published research on gliomas and exosomes,
and connect the findings with those from other areas of exosome research.
Basic science studies investigating gliomas and exosomes, range from
proteomic and genetic characterization of GBM exosomes to evaluating the
11

exosomal influence on tumor neo-angiogenesis.66-73 Bastida and colleague
published the first study on gliomas and exosomes in 1984. Here researchers
demonstrated the presence of tissue factor (TF) in exosomes derived from the U87
human glioblastoma (GBM) line. These TF-laden GBM-derived exosomes had prothrombotic capabilities, which were linked to the activation of the coagulation
cascade and promotion of platelet aggregation.66 Svensson, et al., then
demonstrated that TF in glioma-derived exosomes could interact with endothelial
cells in a paracrine manner. These TF-laden glioma-derived exosomes could
activate pro-thrombotic properties in recipient endothelial cells under hypoxic
conditions.67 These studies highlighted the role of glioma-derived exosomes in tumor
thrombosis. However, the majority of basic science exosome research in gliomas
focuses on their content. In 2008, Al-Nedawi, et al., identified the mutant EGFRvIII in
exosomes derived from glioma cells. This EGFR variant is oncogenic due to
constitutive activity, and exosomes mediated the transfer to non-EGFRvIII
expressing glioma cells.68 This study was the first to demonstrate exosomemediated transfer of tumor-promoting proteins, and laid the foundation for exosome
characterization. The first profiling of glioma-derived exosomes was performed by
Graner and colleagues.69 Here researchers described the presence of mutant
EGFRvIII, as well as immunosuppressive TGF-β, within exosomes released into the
systemic circulation by gliomas.69 Research then shifted to the genetic profiling of
glioma-derived exosomes. Guescini, et al., showed that exosomes secreted by GBM
cells harbored mitochondrial DNA (mtDNA), but not nuclear DNA (nDNA). These
exosomes mediated the transfer of mtDNA to neighboring cells, which could
modulate mitochondrial activity.70 This exosomal transfer of genetic elements
represented a new mechanism of intercellular communication in gliomas.
Subsequently, Bolukbasi and colleagues reported the presence of specific
nucleotide (nt) sequences in the 3’UTR of mRNA in glioma cells that resulted in
targeted enrichment into exosomes for transport out of the cell. This 25nt “zip-code”
sequence also contained a complementary binding site for miR-1289, which was
found to play a role in the enrichment process into glioma-derived exosomes.71
Furthermore, Li, et al., identified the enrichment of non-coding RNA, particularly
12

miRNA and vault-RNA (vtRNA), in glioma-derived exosomes. Interestingly, they also
described the miRNA profile of these exosomes as distinct compared to the glioma
cells from which they originate.72 These studies uncovered the significant amount of
genetic material present in glioma-derived exosomes, however this characterization
did not yet correlate with function. In 2013, Kucharzewska and colleagues, described
hypoxic enhancement of mitogenic and angiogenic properties in glioma-derived and
tumor stroma-derived exosomes. When compared to normoxic conditions, gliomaderived exosomes contained increased levels of matrix metalloproteinases (MMPs),
IL-8 and PDGFs, when isolated under hypoxic conditions. Similarly, exosomes
derived from hypoxic endothelial cells harbored increased levels of growth factors
and cytokines which stimulated PI3K/AKT signaling in pericytes. 73 Together, these
basic science papers demonstrate the broad range of exosome function in gliomas,
and highlight the need for further investigation of exosomes in other areas of glioma
biology.
Translational studies explored patient oriented applications from exosomal
RNA and immunologic therapeutic strategies to the diagnostic and prognostic
utilities of exosomes.74-81 Recently, Katakowski and colleagues found that GBM cells
had decreased levels of miR-146b when compared to normal human astrocytes,
which also held true for the 9L rat glioma cell line. Delivery of BM-MSC-derived
exosomes, packaged with miR-146b, to rat glioma xenografts resulted in decreased
tumor burden, due to miRNA-mediated EGFR down-regulation.74 Additionally,
Munoz, et al., showed that GBM cells had low levels on miR-9, which targets the
drug efflux transporter, P-glycoprotein. Increasing the levels of this specific miRNA in
GBM cells, via delivery of miR-9 laden MSC-derived exosomes, resulted in the
down-regulation of P-glycoprotein, and increased the chemosensitivity of GBM cells
to temozolomide (TMZ).75 Furthermore, Bronisz and colleagues demonstrated that
glioma cells had very low expression of miR-1, and that over-expression of this
miRNA resulted in diminished tumorigenicity. Interestingly, GBM cells which were
modified to over-express miR-1, released exosomes that were enriched in miR-1.
These miR-1 laden GBM cell-derived exosomes decreased tube formation of human
brain microvascular endothelial cells (HBMVECs) in vitro, as well as increased the
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invasion of GBM cells through the extracellular matrix in vivo.76 The findings from
these studies support the investigation and utilization of miRNA-packaged exosomes
as a therapeutic strategy. In the area of tumor immunology, Bu, et al., demonstrated
that glioma-derived exosomes contained tumor antigens that were recognized by
recipient antigen-presenting dendritic cells. After exposure to glioma-derived
exosomes, dendritic cells were able to activate T-lymphocytes that had robust
cytotoxic activity against autologous glioma cells.77 This study highlighted the
potential for the use of tumor-derived exosomes as a vaccine for immunization
against gliomas. With regard to treatment of gliomas with ionizing radiation, Arscott
and colleagues showed the increase of connective tissue growth factor (CTGF)
mRNA and insulin-like growth factor binding protein 2 (IGFBP2) in glioma-derived
exosomes after glioma irradiation. Furthermore, exosomes derived from irradiated
gliomas promoted the activation of neurotrophic tyrosine kinase receptor type 1
(TrkA) and proto-oncogene tyrosine-protein kinase Src, in recipient non-irradiated
glioma cells. Delivery of growth factors and kinase activation resulted in an increase
in glioma cell migratory and invasive properties.78 This study indicates that presurgical radiation of gliomas may promote further invasion of glioma cells that have
escaped radiation-induced cell death. Thus, this mechanism may play a role in
tumor recurrence at the surgical margins. With respect to the diagnostic properties of
exosomes, Noerholm and colleagues found that glioma-derived exosomes, isolated
from the serum of glioma patients, contained numerous RNA elements including a
significant amount of small non-coding RNA species < 500nt in length. This
exosome RNA profile was distinct from that of exosomes derived from normal
subjects, specifically in the down-regulation of 121 genes, many of which encoded
for ribosomal proteins.79 This study outlined the potential for profiling of intraexosomal content as a diagnostic approach in gliomas. However, other researchers
sought to utilized exosomal surface markers as an alternative diagnostic method.
Skog, et al., found that glioma-derived exosomes carried numerous mRNA, miRNA
and angiogenic proteins, which were functional upon transfer to recipient cells in the
tumor.80 This exosomal communication facilitated neovascularization and promoted
proliferation of tumor stroma cells.

Interestingly, many of these glioma-derived
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exosomes were able to escape into the circulatory system due to blood-brain barrier
breakdown in the tumor. These circulating glioma-derived exosomes were found to
contain glioma markers, particularly mutant EGFRvIII, and could be used as an
adjunct diagnostic tool.80 Subsequently, Shao and colleagues, developed micronuclear magnetic resonance (µNMR) techniques to analyze exosomes from the
serum of glioma patients. When compared to serum-exosomes from normal
subjects, those from glioma patient had increased expression of EGFR, EGFRvIII,
podoplanin (PDPN), and mutant isocitrate dehydrogenase 1 (IDH1) R132H. Analysis
of this panel of markers by µNMR resulted in a glioma diagnostic test with 90%
sensitivity and 85% specificity. The glioma marker panel was also shown to have
prognostic

capabilities

by

predicting

patient

response

to

temozolomide

chemotherapy.81 This important study supports the utilization of glioma-derived
exosomes for both diagnostic and prognostic purposes. Together, the findings from
these translational studies demonstrate the practicality and efficacy of exosome
research towards improving patient outcomes.
Importantly, in every basic science and translational study discussed above,
the research is focused on investigating exosomes derived from the tumorpropagating glioma cells and not exosomes released by cells in the surrounding
microenvironment. To my knowledge there are no published studies evaluating the
role of tumor stroma-derived exosomes in the development and evolution of glioma.
Investigation into this aspect of glioma biology would add to the growing body of
knowledge for glioma and exosomes, and is crucial to fully understand this complex
tumor system. This will translate to more effective therapeutic strategies against
gliomas in the future.
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1.3 The Glioma Microenvironment
Cancer is the second leading cause of death in the United States, falling just
behind heart disease, and will account for over half a million deaths in 2014. Of the
wide range of malignant neoplasms, lung, colon, breast, pancreatic and prostate
cancers will be responsible for nearly 55% of those fatalities.82 Rare in comparison,
brain tumors only account for 2.5% of cancer related deaths in United States
citizens, 80% of which will be the result of primary malignant gliomas. However, the
incidence and prevalence of gliomas is increasing. Additionally, the course of the
disease process is among the most devastating, with a majority of patients
succumbing to the disease within the first year, and less than 5% living beyond 5
years after diagnosis.83-84 Furthermore there is no way to screen for, or prevent,
gliomas. People can avoid smoking to decrease their risk of lung cancer. Females
can be screened for breast cancer by receiving regular mammograms. Males can be
screened for prostate cancer by obtaining regular prostate exams. Colon cancer can
be discovered early during routine colonoscopy screenings. These preventative and
early diagnostic measures are not available in glioma, and patients typically present
late in the disease process. If caught early enough, a few of the other cancer types
can be treated with a combinations of radiation, surgery and chemotherapy, and
many patients given the designation of “in remission” or “cured”. Unfortunately this is
rarely the case with glioblastoma (GBM), the most common primary malignant
glioma in adults. Instead, clinicians tend to speak realistically in terms of life
extension rather than cancer free outcomes. Thus, these bleak results are the
driving force for new research into the full understanding of gliomas.
One of the major discoveries in the last decade was the characterization of
glioma propagating cells isolated from patient tumor samples.85-87 Investigation of
these cells in tumor development is the focus of a majority of glioma research.
Additionally, study of these cells aided in the development of a wide range of
therapeutic strategies aimed at eradicating gliomas.88 However, glioma propagating
cells are only one of the cell types present in any given tumor, with many other cells
establishing an intricate support network termed the glioma microenvironment.89
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Cancer stem cells (CSCs) were first described by Bonnet and Dick in
leukemia in 1997, and subsequently described in gliomas by Singh, et al, in 2003,
and Galli, et al., in 2004.85-87 These cells possessed stem-like properties, particularly
the ability to undergo asymmetric replication (self-renewal) and multi-lineage
differentiation (potency).90 Furthermore, when compared to normal brain tissue,
brain CSCs, also known as glioma stem cells (GSCs), expressed many genetic
aberrations that promote cell proliferation and inhibit apoptosis. These properties
were termed oncogenic, and subsequently linked to the presence of several tumor
promoting genes, termed oncogenes, found in GSCs; mitogen-activated protein
kinase (MAPK), mitogen-activated protein kinase kinase (ERK), retrovirusassociated sequences (RAS), cellular myelocytomatosis (c-MYC), and protein
kinase B (Akt).91-96
Work performed in the Lang laboratory before I joined included the isolation of
GSCs from patient surgical specimens, by adapting the protocol published by Singh
and colleagues.86 Briefly, after enzymatic digestion of the gross tumor sample, GSCs
were identified by non-adherent neurosphere growth in serum-free neural stem cell
medium (Figure 4). Isolated GSCs were also found to express the known neural
stem cell marker CD133 (Figure 5).86 Lastly, GSCs were able to form tumors when
implanted as xenografts into the brains of nude mice (Figure 6). Importantly, GSCs
harbored the same genetic aberrations known to be present in many glioblastomas
(Figure 7).96 The isolation of these GSC lines formed the basis for my future
experiments into the glioma microenvironment and novel therapeutic strategies. 97 To
date, 40 GSC lines have been isolated, characterized, and genetically profiled.
After the discovery of GSCs, trials of various targeted therapeutic agents,
including viral vectors, vaccines, and stem cell therapies, were pursued in hopes of
decreasing the collateral damage to non-cancerous cells caused by traditional
radiation and chemotherapy.98-99 However, the combination of surgery, radiation,
plus concomitant and adjuvant temozolomide (TMZ) chemotherapy remains the
standard of care for all malignant gliomas, as described by Stupp and colleagues in
2005.100 The Stupp protocol extends survival from less than one year to nearly 15
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A

B

Figure 4. GSC exhibit specific morphology in cell culture. (A) Nonadherent growth of GSC 262 as a classical neurosphere in neural stem cell
medium. (B) Non-adherent growth of GSC 20 as a non-classical neurocluster in
neural stem cell medium.
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CD133

Figure 5. GSCs express a
glial stem cell marker.
Flow cytometry histogram
for GSC 262 demonstrating
the expression of the
CD133 neural stem cell
97
marker.
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A

B

Figure 6. GSCs are tumorigenic. (A) H&E staining of histologic
sections though the brain of untreated control mice euthanized 30
days after the sham injection procedure, demonstrating no tumor
growth. (B) H&E staining of histologic sections through glioma
xenografts from mice euthanized 30 days after implantation of
97
GSCs, demonstrating significant tumor growth.
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Figure 7. GSCs harbor known mutations of gliomas. Oncoscan assay for GSC 262
demonstrating a gain of function in chromosome 7, and a loss of function in chromosome 10,
97
consistent with known amplifications and deletions described in gliomas.
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months, and since its inception there have been no studies in which outcomes have
improved using any of the new therapeutic strategies targeted against GSCs. One
reason may be the lack of a full understanding of the complex microenvironment of
gliomas. This microenvironment not only involves the GSC component, but also
includes the tumor stroma which is composed of many other cell types.
The idea of a nurturing tumor microenvironment is not new, and was first
postulated by the English surgeon Stephen Paget in 1889. 101 In his paper, Dr. Paget
referred to malignancy as a combination of “seed and soil”, in which neither on their
own could grow a “plant”. Thus, the idea of a cultivating microenvironment for cancer
cells to grow and develop into a tumor was born. Interestingly, Dr. Paget also added
that some tumors had a predisposition for metastasis to specific organs.101 A century
later in 1989, the “seed and soil” theory was finally validated by Halachmi and
colleagues, when they found that the tumor microenvironment has a positive effect
on tumor growth. Specifically, they demonstrated that cancer cells passaged in vivo,
were more tumorigenic compared to those cultured in vitro.102
The description of a microenvironment in gliomas was elucidated by Chen, et
al, in 1993. In their seminal paper, researchers showed that tumor necrosis factoralpha (TNF-α) secreted by astrocytes in the tumor stroma, increased the proliferation
rate of malignant astrocytoma cell lines.103 These studies outlined processes by
which the surrounding cytoarchitecture of a tumor can significantly affect the
progression of the disease. To date, endothelial cells, perivascular cells, immune
cells, and organ parenchymal cells and organ stem cells have been described as
part of this tumor niche. For gliomas, this includes the endothelium, pericytes,
microglia, astrocytes and neural stem cells.89,

104-105

Of these cell types, each has

been implicated in creating pro-glioma conditions in which the malignancy will thrive
and progress. Endothelial cells, which function to maintain the blood-brain barrier in
normal brain tissue, have been shown to secrete mitogenic factors that increase the
self-renewal and invasiveness of GSCs.106-107 Pericytes which form a framework for
the neuro-vasculature, have been found to stabilize tumor neovascularization as well
as suppress the immune response to the malignancy. 108-109 Microglia, which are the
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resident immune cells in the brain, have also been found to increase tumor
invasiveness and induce immunosuppression within gliomas.110-111 Astrocytes, the
local parenchymal cells, can increase tumor cell survival as well as decrease the
activation of the immune system.112-113 Finally, neural stem cells, which are capable
of differentiating into neurons, astrocytes and oligodendrocytes, are readily recruited
to the hypoxic environment of the tumor site. Once incorporated into the tumor
niche, neural stem cells may undergo malignant transformation.114-115 Thus, the
synergistic nature of tumor propagating GSCs and the nurturing glioma
microenvironment may contribute to the inadequacy of current glioma therapy which
does not target both. To effectively combat this devastating disease, requires full
working knowledge not only of the genetic aberrations and tumorigenic features of
GSCs, but also an understanding of the mechanisms by which the glioma
microenvironment supports the malignancy. This knowledge will facilitate the
development of more effective therapies aimed at both the tumor propagating cells
and the tumor stroma.116
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1.4 Glioma-Associated Mesenchymal Stem Cells
In 1963, Becker, McCulloch and Till first demonstrated that transplanted bone
marrow cells in mice could undergo clonal expansion in the spleen.117 Researchers
showed that these cells were undifferentiated, but under certain culturing conditions
were able to differentiate along mesodermal lines. Specifically, these progenitor cells
were able to differentiate into the mesenchymal subtypes: osteocytes, chondrocytes
and adipocytes. Furthermore, these cells replicated by asymmetric division creating
one clonal cell identical to the parental cell, and one daughter cell programmed for
differentiation. These transplanted bone marrow cells were the “stem” of multiple
mesenchymal lineages, and were termed mesenchymal stem cells (MSCs).117
During the evolution of MSC research, the definition of a mesenchymal stem
cell became inconsistent and non-uniform between research groups. For this reason
the International Society for Cellular Therapy (ISCT) established a discrete set of
requirements to denote mesenchymal stem cells.118 In addition to MSCs being
undifferentiated and multipotent, they must grow adherent in in vitro culture with
spindle morphology. Furthermore, the MSCs must express the mesenchymal
surface markers, CD73 (ecto-5’-nucleotidase), CD90 (thymocyte differentiation
antigen-1), and CD105 (endoglin), and lack the hematopoietc stem cell marker
CD34 (platelet/endothelial cell adhesion molecule-1), the panleukocyte marker CD45
(protein tyrosine phosphatase, receptor type, C), and the neural stem cell marker
CD133 (Prominin 1).119-121 These parameters ensured that research groups were
conducting investigations utilizing a consistent and uniform definition of an MSC.
After the discovery of MSCs from human bone marrow (BM-MSCs), stem
cells were found in other organ systems. Importantly, in 1989, Temple demonstrated
progenitor cells in the subventricular zone (SVZ) of adult human brains, termed
neural stem cells (NSCs).122 Later, research groups began exploring cancer for stem
cells, given that tumor growth results from a clonal expansion of cells.123 After the
discovery of cancer stem cells (CSCs) in 1997, and glioma stem cells (GSCs) in
2003, researchers began looking for non-tumor propagating stem cells within the
tumor stroma of various malignancies.85-86 One cell of focus in tumors was MSCs
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due to their ability to home to sites of tissue injury to aid in wound healing.124-126 The
similarities between tumors and chronic wounds are well established, considering
the damage to surrounding stromal structure that occurs as a malignancy grows. 127
Therefore it is reasonable that MSCs would home to tumors to participate in tissue
repair. In 2001, Wallace and colleagues first identified MSCs within primary sites of
multiple myeloma.128 These tumor-associated MSCs (TA-MSCs) were found in the
perivascular niche of the tumor and were distinct from tumor-propagating plasma
cells in both morphology and genetic profile. TA-MSCs were subsequently described
in breast, prostate and lung cancer.129-131 Cancer stem cells were then shown to
produce certain chemotactic factors that promoted the recruitment of MSCs to the
primary tumor sites.132 Additionally, the phenomenon of MSC recruitment was first
demonstrated in vivo by Kidd and colleagues in 2009, using a mouse model to show
the localization of systemically delivered luciferase-labeled MSCs to breast cancer
xenografts.133 Interestingly, this homing functionality of MSCs prompted investigation
into their use as a delivery vector for anti-cancer agents, such as interferon-β.134-135
Thus, MSCs are now accepted as a distinct component of the tumor stroma.
Mesenchymal stem cells were only recently demonstrated in normal brain
tissue by Paul and colleagues in 2012.136 Researchers found a subgroup of cells
resembling pericytes lining the cerebral microvasculature in select areas of the brain.
However, unlike pericytes, these cells expressed many of the mesenchymal
markers, but lacked endothelial, microglial, hematopoietic, glial, and neural stem cell
markers. Additionally, these cells had stem-like properties in their ability to
differentiate along mesodermal lines.136 These results show that MSCs are present
in the microvasculature of normal brain tissue. Since MSCs are known to migrate to
sites of tissue injury, it is reasonable that these organ-specific MSCs may play a role
in the acute repair of local tissue.124-126 Thus, the origin of tumor-associated MSCs
(TA-MSC) could be from locally recruited MSCs in the tumor perivascular niche or
from distantly recruited MSCs from the bone marrow. However, regardless of the
origin, TA-MSCs have never been described in brain tumors. Although MSCs are
known to migrate towards gliomas, and are used as a therapeutic delivery vehicle,
they have never been isolated from patient-derived tumor specimens.137-142
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Research conducted by the Lang laboratory before I joined, focused on the
isolation and characterization of TA-MSCs in gliomas, termed glioma-associated
mesenchymal stem cells (GA-MSCs).97 Initially, surgical specimens were obtained
within 4 hours of resection, and processed in accordance with the protocol published
by Pittenger and colleagues, with a modification for whole tissues. 143 Briefly, after
enzymatic digestion of the gross tumor sample, GA-MSCs were identified by plasticadherent growth in serum-containing cell culture medium (Figure 8). Furthermore,
GA-MSCs expressed the characteristic MSC markers of CD73, CD90 and CD105,
and lacked the hematopoietc marker CD34, the panleukocyte marker CD45, and the
neural stem cell marker CD133 (Figure 9). Lastly, GA-MSCs were able to
differentiate into chondrocytes, adipocytes and osteocytes by growth medium
induction (Figure 10). Importantly, GA-MSCs were genetically distinct from GSCs
isolated from the same specimen (Figure 11), and did not form tumors when
implanted as xenografts into the brains of nude mice (Figure 12). The discovery of
this novel cell line in gliomas prompted further research investigating the intercellular
interactions between GA-MSCs and GSCs, in order to elucidate their function in the
microenvironment.97
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A

B

Figure 8. GA-MSCs exhibit specific morphology in cell culture. (A) GAMSC 262 adherent growth and classical spindle morphology in MSC medium.
(B) GA-MSC 20 adherent growth and classical spindle morphology in MSC
medium.
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CD73

CD90

CD105

CD133

Figure 9. GA-MSCs express known MSC markers. Flow cytometry
histograms for GSC 262 demonstrating the expression of the MSC
markers CD73, CD90 and CD105, and lack of expression of the neural
97
stem cell marker CD133.

28

Adipogenic

Osteogenic

Chondrogenic

Figure 10. GA-MSCs can tri-differentiate along
mesenchymal lines. Light microscopy demonstrating the
characteristic adipocyte, osteocyte and chondrocyte
morphology of differentiated GA-MSCs after culture in
97
differential medium.
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GSC240

GA-MSC240

D10S1683
Figure 11. Matching GSCs and GA-MSCs do not
harbor the same genetic mutations. Chromosomal
analysis demonstrating loss of heterogeneity for
chromosome 10 in GSC 240, which is preserved in the
matching GA-MSC 240 isolated from the same patient
97
tumor.
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B

A

Figure 12. GA-MSCs are not tumorigenic. (A) H&E staining of
histologic sections though the brain of untreated control mice
euthanized 30 days after the sham injection procedure. (B) H&E
staining of histologic sections through the brains of mice euthanized
97
30 days after implantation of GA-MSCs.
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1.5 The Role of Mesenchymal Stem Cells in the Tumor Niche
The fact that BM-MSCs are recruited to primary tumor sites was initially
attributed to a role in maintenance and growth of the perivascular niche. However,
soon after their description as part of the tumor microenvironment, research began
on the interactions between BM-MSCs and CSCs. In 2007, Karnoub and colleagues
first demonstrated the tumor-promoting capabilities of BM-MSCs on breast cancer
stem cells.144 Researchers found that co-injection of BM-MSCs and breast cancer
stem cells in mice resulted in increased invasion and metastasis. Interestingly, this
phenomenon was linked to the secretion of chemokine cytokine ligand 5 (CCL5) by
the BM-MSCs. CCL5 would then act via a paracrine mechanism to stimulate the
motility of neighboring breast cancer stem cells.144 Subsequently, the tumorpromoting properties of MSCs were described in other malignancies, such as colon
and prostate cancer.145-148 Interestingly, the enhancement of tumors was not limited
to the promotion of metastasis, but also included induction of immunosuppression
and advancement of tumor growth.149-150 However, each of these studies utilized
BM-MSCs in their investigations, and did not examine the tumor-promoting
properties of native TA-MSCs isolated from the tumor microenvironment.
Research accomplished by the Lang laboratory before I joined, investigated
the interaction between GA-MSCs and GSCs.97 Results from this study were the first
demonstration of GA-MSCs promoting the growth and aggressive nature of gliomas.
In vitro co-culture experiments showed that GA-MSCs increased the proliferation
and clonogenicity of GSCs, when compared to untreated controls (Figure 13).
Additionally, the co-implantation of GA-MSCs and GSC into the flanks of mice
resulted in a decrease in median survival (Figure 14). Furthermore, tumor burden
was significantly increased with co-implantation of GA-MSCs and GSCs into the
flanks of mice (Figure 15). These glioma-promoting properties were linked to the
secretion of interleukin-6 (IL-6) by GA-MSCs into the extracellular space and
subsequent utilization by neighboring GSCs (Figure 16). Lastly, the IL-6 mediated
tumor-promoting effects were found to be the result of downstream activation of the
JAK/STAT3 pathway in GSCs. (Figure 17).97
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Figure 13. GA-MSCs promote the
growth and self-renewal of GSCs. (A)
Proliferation assay for 3 GSC lines
demonstrating significant increases in
viability after culturing in conditioned
medium derived from BM-MSC and 2
GA-MSC lines. (B) Clonogenic assay for
3 GSC lines demonstrating a significant
increase in neurosphere formation after
culturing in conditioned medium derived
97
from BM-MSC and GA-MSC.
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Figure 14. GA-MSCs decrease median
survival in mice with GSC xenografts.
Survival curve for GSC 7-2 demonstrating a
significant decrease in median survival after
97
co-injection with BM-MSC and GA-MSC 230.
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Figure 15. GA-MSCs increase tumor burden in
mice with GSC xenografts. Flank tumors for mice
with GSC 7-2 xenografts demonstrating an increase
in tumor burden after co-injection with BM-MSC and
97
GA-MSC 230.
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97
after treatment with IL-6.

36

C

hMSC230
+hBMEC

+GA-hMSC230
hMSC

media
+BM-hMSC

NSC media
C

+hBMEC
hMSC230

+GA-hMSC230
hMSC

NSC media

media
+BM-hMSC

A

p-STAT3
Total STAT3
Tubulin

0.06

0.04

*

0.02

Average number of
spheres/96 well

0
NSC media
+
GA-hMSC230 GA-hMSC240 WP1066 (mM) 0

C

GSC23

450)

B

Proliferation (OD at 450)

GSC7-2

- + + + +
- 0 0.1 1 10

+ + +
0 0.1 1

+
10

50
40
30

*

*

20

*

10
+

-

-

-

-

-

-

-

-

GA-hMSC230 GA-hMSC240 -

NSC media

+
-

+
-

+
-

+
-

+

+

+

+

10

0

0.1

WP1066 (mM) 0

0 0.1 1

1

10

Figure 17. IL-6 secretion from GA-MSCs activates STAT3. (A) Western blot
analysis for GSC demonstrating increased p-STAT3 expression after co-culture
with BM-MSC and GA-MSC 230. (B) Proliferation assay for GSC demonstrating
significant dose dependent decreases in viability after treatment GA-MSC and
STAT3 inhibitor (WP1066). (C) Proliferation assay for GSC demonstrating dose
dependent decreases in neurosphere formation after treatment with GA-MSC
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and STAT3 inhibitor (WP1066).
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The findings from studies investigating the role of MSCs in gliomas, and thus
the intercellular communication between MSCs and GSCs, is limited to the
description of soluble tumor-promoting proteins by MSCs. However, one key
component of paracrine intercellular interactions that has been overlooked is that of
exosome communication. Although the physiologic and pathologic release of
exosomes has recently been investigated in a variety of disease processes,
including cancer, the function of exosomes secreted from non-cancerous cells within
the tumor niche has never been explored.151 This research disparity, combined with
the extensive evidence describing the various contents of exosomes, highlights a
gap in knowledge as to the function of MSC-derived exosomes. Thus, further
examination

is

necessary

to

evaluate

this

novel

intercellular

exosomal

communication pathway between MSCs and GSCs.
Currently, there are only two reports investigating the role of tumor stromaderived exosomes within the microenvironment. In 2013, Luga, et al., found that
exosomes released from cancer associated fibroblasts (CAFs) in breast cancer,
increased the invasion and motility of breast cancer cells. 152 This effects was linked
to the activation of the Wnt-planar cell polarity (Wnt-PCP) signaling pathway, via
Wnt11 molecules packaged in CAF-derived exosomes. Luga and colleagues
concluded that this intercellular communication system led to enhanced metastatic
capabilities of breast cancer.152 This is the first study demonstrating the tumorpromoting capabilities of exosomes derived from stromal cells isolated from the
tumor microenvironment. Recently, in 2014, Wang and colleagues, demonstrated
that exosomes from gastric carcinoma-mesenchymal stem cells (GC-MSCs) were
capable of increasing the growth and migration of human gastric carcinoma (HGC)
cells.153 These effects were found to be mediated by the delivery of miR-221 to HGC
cells by GC-MSC-derived exosomes. The onco-miRNA miR-221 is linked to the
down-regulation of certain cyclin dependent kinase inhibitors and anti-apoptotic
factors.153 Together these two studies demonstrate the tumor-promoting role of
stroma-derived exosomes, and define a mechanism by which the exosomal contents
can mediate the tumor-enhancing effects.
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Another study published by Roccaro, et al., showed the tumor-promoting
properties of BM-MSC-derived exosomes in multiple myeloma (MM), albeit using
cells that were not part of the microenvironment in the primary tumor. 154 Here
researchers found that MSCs harvested from the bone marrow (BM-MSCs) of
patients with MM, had different genetic and proteomic profiles than BM-MSCs
harvested from normal subjects. These differences carried over to differences in the
genetic and proteomic profiles of exosomes derived from both BM-MSC lines.
Roccaro and colleagues found that BM-MSC-derived exosomes from MM patients
had higher levels of levels of oncogenic proteins, cytokines and adhesion molecules,
when compared to BM-MSC-derived exosomes from normal subjects. These tumor
promoting proteins were shown to transfer to plasma cells in both in vitro and in vivo
mouse models.154 Importantly, the BM-MSCs of MM patients were harvested from
abnormal bone marrow, not primary tumor sites, and therefore not associated with
the microenvironment. However, MM is thought to arise from abnormal bone
marrow, and these abnormal BM-MSCs may play a role in the initial malignant
transformation of plasma cells in MM.154 Nevertheless, this study demonstrates the
tumor-promoting capabilities of exosomes derived from BM-MSCs, which can be
recruited to, and engrafted in, gliomas.
In 2011, Zhu, et al., investigated the tumor promoting effects of BM-MSCderived exosomes on human gastric carcinoma and colon cancer cell lines. 155 They
found that tumor stem cells treated with BM-MSC-derived exosomes had increased
proliferation in vitro, and promoted tumorigenicity in in vivo mouse xenografts.
Additionally, they showed that these results were due to the increased expression of
vascular endothelial growth factor (VEGF) in the cancer stem cells, via exosomal
activation of extracellular signal-regulated kinase 1/2 (ERK1/2).155 Their findings
suggested a novel mechanism by which intercellular communication could take
place within a tumor.
Although the Roccaro and Zhu articles demonstrate the tumor promoting
properties of BM-MSC-derived exosomes, these cells are not the most accurate
representation of MSCs in the tumor microenvironment. Once recruited and
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entrenched in the tumor niche, BM-MSCs are influenced by neighboring CSCs and
undergo specific changes that alter their biology.156-161 Although they still exhibit the
classical MSC morphology, surface markers, and tri-differentiation capabilities, TAMSCs differ from normal BM-MSCs in proliferation rate and genetic signature.97
Therefore the efficacy of these studies could be improved by investigating the effects
of TA-MSC-derived exosomes on the progression of malignancy. Thus, the focus of
my thesis is the investigation of exosomal communication within the glioma
microenvironment, utilizing GA-MSCs and GSCs isolated from patient tumor.
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1.6 Conclusions
In this chapter I described that exosomes are 40-100nm in diameter with a
lipid bilayer, are formed and packaged intracellularly within the endosomal system,
and are secreted from the cell via exocytosis. I discussed how exosomes are
different from other larger microvesicles, in formation, content and morphology. I
described the specific protein constituents of the exosomal membrane, the cellular
elements that have been found in the intra-exosomal compartment, and how
exosomes interact with recipient cells via fusion or endocytosis. I explored the
studies evaluating exosomes in gliomas, from the transfer of an oncogenic protein
receptor, to diagnostic properties in the serum, to new therapeutic strategies. I
described the constituents of the glioma microenvironment, and how it is nurturing to
resident GSCs. I discussed how we isolated GA-MSCs from glioma surgical
specimens, and that GA-MSC-mediate promotion of tumor growth is link to cytokine
secretion. I described how MSC-derived exosomes promote malignant growth in
other tumor types, but have not been studied in gliomas. Based on this background,
investigating the effects of GA-MSC-derived exosomes on GSCs will provide a
better model to study the role of stroma-derived exosomes in the glioma
microenvironment.
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1.7 Hypothesis
Given the capability of exosomes to participate in paracrine communication
between cells, and also the potential of exosome content to alter the biology of
recipient cells, I hypothesized that GA-MSC-derived exosomes increase the growth
and evolution of gliomas via the delivery of specific miRNA to recipient GSCs. To
test this hypothesis I investigated three specific aims:
1. I hypothesized that GA-MSCs produce exosomes with unique proteomic and
genomic profiles when compared with parental GA-MSCs. To test this
hypothesis, I propose to:
a. Demonstrate that GA-MSCs produce exosomes.
b. Characterize the production system of GA-MSC-derived exosomes.
c. Characterize the content of GA-MSC-derived exosomes.
2. I hypothesized that GA-MSC-derived exosomes can be internalized by GSCs
and can increase the tumorigenicity of GSCs. To test this hypothesis, I
propose to:
a. Demonstrate that GSCs can internalize GA-MSC-derived exosomes.
b. Show that GA-MSC-derived exosomes increase the proliferation and
clonogenicity of GSCs in vitro.
c. Establish that GA-MSC-derived exosomes increase the tumorigenicity
of GSCs in vivo.
3. I hypothesized that MicroRNAs delivered via GA-MSC-derived exosomes
increase the tumorigenicity of GSCs. To test this hypothesis, I propose to:
a. Identify miRNA in GA-MSC-derived exosomes that could potentially
influence the growth of GSCs.
b. Demonstrate that specific miRNA in GA-MSC-derived exosomes
increase the proliferation and clonogenicity of GSCs in vitro.
c. Establish that specific miRNA in GA-MSC-derived exosomes increase
the tumorigenicity of GSCs in vivo.
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Chapter II
Isolation and Characterization of
GA-MSC-Derived Exosomes
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Isolation and Characterization of GA-MSC-Derived Exosomes

Understanding the role of exosomes in the communication between GAMSCs and GSCs requires evidence that GA-MSCs release exosomes, and that
these GA-MSC-derived exosomes contain elements that can alter the biology of
GSCs. To my knowledge there is little information about the production of exosomes
by GA-MSCs and detailing of the content of GA-MSC-derived exosomes has never
been performed. Therefore, I hypothesized that GA-MSCs produce exosomes with
unique proteomic and genomic profiles when compared with parental GA-MSCs. To
test this hypothesis, I first show that GA-MSCs produce nano-vesicles that qualified
as exosomes. These results proved that this tumor stroma constituent is capable of
exosome production. I then determined the extent to which external cellular
stressors affected production of GA-MSC-derived exosomes. These experiments
showed that exosomes are released under conditions that simulate the tumor niche.
Finally, I characterized the content of GA-MSC-derived exosomes; specifically, I
interrogated the protein and miRNA profiles. These experiments identified exosomal
miRNAs that have the potential to alter the biology of GSCs.
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2.1 Experimental Methods
To investigate the role of exosomes in the communication pathway between
GA-MSC and GSCs, I utilized commercially available human BM-MSCs (Lonza, Inc.)
and also GA-MSCs isolated from human glioma surgical specimens. GA-MSCs were
isolated from the surgical specimens by applying the same methods used to isolate
human BM-MSCs.143 I selected four GA-MSCs lines that spanned the range of
glioma grades (Table 1), in order to assess for any exosomal differences among
degree of tumor pathology. All four GA-MSC lines met the criteria for MSCs as
outlined by the International Society for Cellular Therapy (ISCT).118 Specifically, all
GA-MSC lines have spindle shape morphology and are adherent in culture.
Additionally, all GA-MSC lines expressed the mesenchymal surface markers CD73,
CD90 and CD105, and did not express the endothelial surface marker CD34, the
hematopoietic surface marker CD45, or the neural stem cell marker CD133. Finally,
all GA-MSC lines possessed the ability to tri-differentiate into adipocytes,
chondrocytes and osteocytes.118
I also chose four GSC lines which were isolated from human glioma surgical
specimens using the methods described by Singh, et al. (Table 2).86 Importantly, two
of these GSCs (GSC-20 and GSC-262) were isolated from the same tumor
specimens from which were isolated two of the GA-MSC lines (GA-MSC-262 and
GA-MSC-20). This provided us with two matching GA-MSC/GSC pairs. Importantly,
the GA-MSCs are unique from the corresponding GSCs. GA-MSCs do not express
the same genetic aberrations as GSCs, nor do they form tumors in mouse
xenografts as do GSCs.97 Interestingly, GA-MSCs also differ from normal human
BM-MSC in both genetic and growth profiles.97
Isolation of GA-MSC-Derived Exosomes
In order to isolate MSC-derived exosomes, BM-MSCs and GA-MSCs were
expanded to approximately 106 cells in MSC growth medium: Eagle’s Minimum
Essential Medium Alpha (Sigma-Aldrich), 10% fetal bovine serum, 1% penicillinstreptomycin, and 1% glutamine. GA-MSCs were then washed and allowed to
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Adipo- Chondro- Osteogenesis genesis genesis

Grade III
84.4

% CD34 % CD133

GA-MSC 230
Grade IV
99.1

% CD73 % CD73/90/105 % CD45

GA-MSC 247
52.5

Pathology % CD105 % CD90

GA-MSC 262*
Grade IV

Cell Line

GA-MSC 20*

Table 1. GA-MSCs exhibit MSC-like characteristics. GA-MSC lines express the CD73, CD90, CD105 mesenchymal
markers, do not express the CD34, CD45 and CD133 endothelial, hematopoietic, and neural stem cell markers, can
differentiate along mesenchymal lines, and are not tumorigenic (NG = no growth).
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GSC 11

Grade IV

4.0

59.0

In Vivo
Growth
G

GSC 7-2

Grade IV

2.9

75.0

G

GSC 262*

Grade IV

6.4

28.6

G

GSC 20*

Grade IV

4.0

26.0

G

Cell Line

Pathology % CD73/90/105 % CD133

Table 2. GSCs exhibit CSC-like characteristics. GSC
lines express the CD133 neural stem cell marker, do not
express the CD73, CD90 and CD105 mesenchymal
markers, and are tumorigenic in mice (G = growth).
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incubate for 48 hours in serum-free NSC medium: Dulbecco’s Modification of
Eagle’s Medium/Ham’s F-12 50/50 mix with L-Glutamine (Corning CellGro), 2% B-27
supplement (Gibco), and 1% penicillin-streptomycin.
BM-MSC-derived and GA-MSC-derived exosomes were then isolated by
differential ultracentrifugation, as described by Thery, et al.162 Briefly, MSC-derived
conditioned medium was collected and passed through a 22μm filter to remove dead
cells and cellular debris, and centrifuged at 10,000 x gravity for 30 minutes, to
remove large microvesicles (non-exosomal). The supernatant was collected and
ultra-centrifuged at 100,000 x gravity for 90 minutes. The supernatant (exosome-free
conditioned medium) was removed yielding a raw exosome pellet, which was
resuspended in PBS. Exosomes were further purified by another ultra-centrifugation
at 100,000 x gravity, for 90 minutes, with or without a 30% sucrose cushion
depending on the experimental usage. Exosome pellets were then resuspended in
PBS, NSC medium or lysis buffer depending on the experimental need.
Western Blot Analysis of GA-MSC-Derived Exosomes
In order to confirm that nano-vesicles isolated from MSC-derived conditioned
medium were exosomes, I performed western blot for known exosomal markers.
BM-MSC-derived and GA-MSC-derived exosomes were isolated by differential
ultracentrifugation. Protein from BM-MSC-derived and GA-MSC-derived exosomes
was extracted using membrane lysis buffer, and measured by Bradford protein
assay. Western blot for the exosomal surface markers CD63 and GAPDH on MSCderived exosomes, and the corresponding parental cell, were performed using antiCD63

(Santa

Cruz Biotechnology,

Inc.)

and

anti-GAPDH

(Sigma-Aldrich).

Additionally, western blot for the non-exosomal surface markers CD16 and CD32 on
MSC-derived exosomes, and the corresponding parental cell, were performed using
anti-CD16 (Abcam) and anti-CD32 (Abcam).
Electron Microscopic Analysis of GA-MSC-Derived Exosomes
In order to more clearly confirm that nano-vesicles isolated from MSC-derived
conditioned medium were exosomes, I performed electron microscopy analysis to
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visualize morphology. BM-MSC-derived and GA-MSC-derived exosomes were
isolated by differential ultracentrifugation. BM-MSC-derived and GM-MSC-derived
exosomes were prepared for analysis by electron microscopy (EM) by the accepted
protocol published by Thery, et al.162 Briefly, MSC-derived exosomes were affixed to
Formvar coated EM grids using 2% paraformaldehyde (PFA), and contrasted with
4% uranyl-oxalate. MSC-derived exosomes were then examined by electron
microscopy on a JEM 1010 transmission electron microscope (JEOL) at an
accelerating voltage of 80 Kv. Digital images were obtained using the AMT Imaging
System (Advanced Microscopy Techniques). For gold particle (10nm) labeling,
exosome grids were subjected to immuno-gold staining of the exosomal surface
marker CD63 and the non-exosomal markers CD16 and CD32, utilizing gold-antirabbit (Sigma Aldrich), anti-CD63 (Santa Cruz Biotechnology, Inc.), anti-CD16
(Abcam), and anti-CD32 (Abcam). MSC-derived exosomes were then examined by
electron microscopy as previously described.
Characterization of the Production System for GA-MSC-Derived Exosomes
In order to characterize the production system of MSC-derived exosomes, I
utilized various growth conditions and quantified exosomes by ELISA. BM-MSCs
and four GA-MSCs were expanded to 50%, 60%, 70%, 80%, 90% and 100%
confluency, in eight 15cm dishes. Two of the dishes were incubated for 24 hours,
two incubated for 48 hours, two incubated for 72 hours and two incubated for 96
hours. BM-MSC-derived and GA-MSC-derived exosomes were then isolated by
differential ultracentrifugation as previously described. BM-MSC-derived and GAMSC-derived exosomes from each time point in each group, were quantified by
CD63 ELISA (System Biosciences), which utilizes standards calibrated by
NanoSight. Briefly, BM-MSC-derived and GA-MSC-derived exosomes were affixed
to anti-CD63 coated 96-well plates overnight, and subsequently analyzed after the
addition of a secondary antibody, followed by an enzymatic colorimetric substrate.
Later experiments utilized the NanoSight (NS300) system to not only quantify, but
also measure the diameter of isolated exosomes. Briefly, BM-MSC-derived and GAMSC-derived exosomes were resuspended in PBS, diluted 1:100, and passed
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through the laser detector of the NS300. The NS300 utilizes laser light scattering to
visualize the Brownian motion of nano-sized particles. This technology not only
enables the quantification exosomes, but also produces a size distribution which
includes statistical parameters.
Protein Characterization of GA-MSC-Derived Exosomes
In order to characterize the protein content of MSC-derived exosomes, I
utilized protein array technology. BM-MSCs and GA-MSCs were expanded to 2.5 x
107 cells in MSC medium, washed with PBS and cultured in NSC medium for 48
hours. BM-MSC-derived and GA-MSC-derived conditioned medium (CM) was then
collected, subjected to ultracentrifugation, the exosome-free conditioned medium
(EF-CM) supernatant removed and saved, and the MSC-derived exosome pellets
resuspended and lysed in neural stem cell (NSC) medium and lysis buffer. Immunoblot was then performed using human growth factor and cytokine antibody array kits
(Bio Ray), on BM-MSC-derived and GA-MSC-derived CM, BM-MSC-derived and
GA-MSC-derived EF-CM and BM-MSC-derived and GA-MSC-derived exosomes, as
well as the NSC medium/lysis buffer control. Briefly, protein from exosome samples
were affixed to anti-growth factor and anti-cytokine coated array plates overnight,
and subsequently analyzed after the addition of a secondary antibody, followed by
an enzymatic substrate.
MicroRNA Characterization of GA-MSC-Derived Exosomes
In order to characterize the miRNA profile of MSC-derived exosomes, I
utilized miRNA micro-array technology. BM-MSC-derived and GA-MSC-derived
exosomes were isolated by differential ultracentrifugation, and exposed to RNase
(1nM) for 15 minutes to eliminate free-floating extra-vesicular RNA elements.
Remaining RNase was removed by PBS wash and subsequent centrifugation. Total
RNA was then extracted by a combination of organic and solid-phase methods using
the mirVana RNA isolation kit (Ambion). Additionally, total RNA was extracted from
the parental cell line, and the miRNA profile for each sample was obtained using
µParaflo® microfluidic biochip technology, through LC Sciences (Houston, TX).
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2.2 Results
Characterization of GA-MSC-Derived Exosomes
One of the established methods for identifying exosomes is by western blot
for tetraspanin membrane proteins and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), both of which are commonly associated with exosomes. Consequently,
we cultured and isolated nano-vesicles from BM-MSCs and GA-MSCs (see
experimental methods). Western blot results show the presence of CD63, a member
of the tetraspanin family, as well as GAPDH in the protein extracted from isolated
nano-vesicles from BM-MSC and GA-MSCs (Figure 18). Additionally, the nonexosomal markers, CD16 and CD32, were absent in nano-vesicle isolates from BMMSC and GA-MSCs, although they were present in parental MSCs.163 These results
indicate that the isolated MSC-derived nano-vesicles were exosomes.
In addition to harboring specific membrane protein constituents, exosomes
are also characterized by specific size and shape criteria as outlined by Thery, et
al.162 However, the size of exosomes limits their visualization by conventional light
microscopy, and electron microscopy (EM) is the gold standard for characterizing
the morphology of exosomes. Therefore we used EM to further characterize the
nano-vesicles isolated from BM-MSCs and GA-MSCs. EM of nano-vesicle isolates
from BM-MSC and GA-MSCs demonstrate round nano-vesicles 40-100 nm in
diameter, with a lipid bilayer, consistent with the known appearance of exosomes
(Figure 19). To more precisely define these nano-vesicles as exosomes, we labeled
the CD63 membrane protein with gold nano-particles. EM after immuno-gold
staining against CD63, confirmed the presence of the tetraspanin exosomal marker
in the membrane of these nano-vesicles. Furthermore, immuno-gold staining against
CD16 and CD32 by EM, demonstrated the absence of these markers in the
membrane of these nano-vesicles (Figure 20). These methods provided strong
evidence that the nano-vesicles produced by BM-MSCs and GA-MSCs meet the
criteria of exosomes.
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Figure 18. MSC-derived nano-vesicles express exosomal markers. Analysis of
the exosomal markers CD63 and GAPDH, as well as the non-exosomal markers
CD32 and CD16, in exosomes derived from BM-MSC and four GA-MSC lines.
CD63 is expressed in all MSC-derived exosomes, and expression is higher than in
the parental cell. GAPDH is also expressed in all MSC-derived exosomes, however
expression is higher in the parental cell. Both CD32 and CD16 are not expressed
in all MSC-derived exosomes, but are expressed in the parental cell.

52

BM-MSC

500nm

GA-MSC
230

500nm

GA-MSC
247

500nm

GA-MSC
262

500nm

GA-MSC
20

500nm

Figure 19. Morphology of MSC-derived nano-vesicles is identical to exosomes.
Analysis of exosomes derived from BM-MSC and four GA-MSC lines, by scanning
electron microscopy. Exosomes derived from all MSC lines exhibit the classical
cupped-shape morphology with a distinct lipid bilayer, and are within the 40nm-100nm
range.
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Figure 20. Exosome marker is expressed on MSC-derived nano-vesicles.
Immuno-gold labeling of the exosomal marker CD63, and non-exosomal markers
CD32 and CD16, of exsomes derived from BM-MSC and four GA-MSC lines. (Top
Panel) Gold anti-body can bind to and label CD63 expressed on the membrane of
all MSC-derived exosomes. (Middle/Bottom Panels) Gold anti-body cannot
recognize any CD32 or CD16 markers in all MSC-derived exosomes.
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The size of BM-MSC-derived and GA-MSC-derived exosomes was further
verified by utilizing NanoSight technology, which can determine both the diameter
and number of exosomes. Results from NanoSight analysis show the size
distribution of BM-MSC-derived and GA-MSC-derived exosomes to be within the
established 40-100nm range for exosomes (Figure 21). Interestingly, the average
diameter of exosomes derived from BM-MSCs and GA-MSCs were not significantly
different (p > 0.05, student’s t-test). These data correlated with results of the western
blot and electron microscopy analysis, and further supported the classification of the
isolated BM-MSC-derived and GA-MSC-derived nano-vesicles as exosomes.
Production of GA-MSC-Derived Exosomes Under Cellular Stress
In order to understand the influence of culture conditions on exosomal
production, we plated BM-MSCs and GA-MSCs at varying confluency and isolated
exosomes at different time points (see experimental methods). These experiments
aimed to mimic the tumor microenvironment by increasing the cell culture time,
leading to decreased nutrients, as well as culturing cells at increasing levels of
confluency, leading to more cell-to-cell contact. Under these conditions, BM-MSC
and GA-MSCs initially increase their exosome production rate as nutrients are being
used and cell-to-cell contact increases (Figure 22). However after 48 hours culture
time and 70-80% confluency, BM-MSC-derived and GA-MSC-derived exosome
production begins to decline. These results indicate that both BM-MSCs and GAMSCs respond to cellular stress by decreasing exosome production, most likely for
conservation of energy.
Growth Factor Content of GA-MSC-Derived Exosomes
GA-MSC-derived exosomes may alter the growth of GSCs via delivery of
growth factors that can activate receptors on the recipient cell, or by transfer of
growth factor receptors that are then incorporated into the membrane of the recipient
cell. Therefore, I utilized protein array technology to analyze 33 growth factors and
8 growth factor receptors in BM-MSC-derived and GA-MSC-derived exosomes
(Table 3). Specifically, BM-MSCs and GA-MSCs were cultured and protein was
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A. BM-MSC

B. GA-MSC 230

D. GA-MSC 262

C. GA-MSC 247

E. GA-MSC 20

Figure 21. MSC-derived nano-vesicles exhibit exosome size
distribution. (A) BM-MSC-derived exosomes have a mean diameter of
95nm. (B) GA-MSC 230-derived exosomes have a mean diameter of 94nm.
(C) GA-MSC 247-derived exosomes have a mean diameter of 74nm. (D) GAMSC 262 derived exosomes have a mean diameter of 95nm. (E) GA-MSC
262-derived exosomes have a mean diameter of 83nm.
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Figure 22. MSC-derived exosomes exhibit specific production
systems. (A) Exosome production system for BM-MSC
9
demonstrating a maximum of 7.87 x 10 exosomes produced at
80% confluency and 72 hours in culture.
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Figure 22. MSC-derived exosomes exhibit specific production
systems. (B) Exosome production system of GA-MSC 230
9
demonstrating a maximum of 7.39 x 10 exosomes produced at
70% confluency and 72 hours in culture. (C) Exosome production
9
system of GA-MSC 247 demonstrating a maximum of 7.57 x 10
exosomes produced at 80% confluency and 72 hours in culture.
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Figure 22. MSC-derived exosomes exhibit specific production
systems. (D) Exosome production system of GA-MSC 262
9
demonstrating a maximum of 8.03 x 10 exosomes produced at
70% confluency and 48 hours in culture. (C) Exosome production
9
system of GA-MSC 247 demonstrating a maximum of 8.51 x 10
exosomes produced at 70% confluency and 48 hours in culture.
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Table 3. GA-MSC-derive exosomes do not contain major growth factors. Growth
factor immuno-blot array for 33 major growth factors and 8 major growth factor
receptors.
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extracted from isolated exosomes and analyzed by immune-blot (see experimental
methods). As controls, I utilized BM-MSC-derived and GA-MSC-derived conditioned
medium (CM), BM-MSC-derived and GA-MSC-derived exosome-free conditioned
medium (EF-CM), and neural stem cell (NSC) medium alone (Figure 23). GA-MSCderived exosomes had the same growth factor profile as the neural stem cell
medium alone, with the presence of four growth factors: granulocyte colony
stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GMCSF), insulin-like growth factor-2 (IGF-II), and transforming growth factor-β (TGF- β).
These data indicate that GA-MSC-derived exosomes did not contain any of the
growth factors or growth factor receptors analyzed by the protein array. In contrast,
several growth factors, such as platelet-derived growth factor-AA (PDGF-AA),
insulin-like growth factor binding-protein-2 (IGFBP-2), and vascular endothelial
growth factor (VEGF), are present in GA-MSC-derived CM (which contains a low
concentration of exosomes), and matches the profile seen in the GA-MSC-derived
EF-CM after ultra-centrifuge extraction of exosomes. Therefore, removing exosomes
from GA-MSC-derived CM does not eliminate or decrease growth factor signatures.
These data indicate that, whereas GA-MSC-derived CM and EF-CM contain soluble
growth factors secreted by the cell, these growth factors and growth factors
receptors are not present within BM-MSC-derived and GA-MSC-derived exosomes.
Profiling of Cytokines in GA-MSC-Derived Exosomes
GA-MSC-derived exosomes may also affect GSCs by delivering cytokines.
Therefore, I utilized protein array technology to analyze 59 cytokines and 1 cytokine
receptor

in

BM-MSC-derived

and

GA-MSC-derived

exosomes

(Table

4).

Specifically, BM-MSCs and GA-MSCs were cultured and protein was extracted from
isolated exosomes and analyzed by immune-blot (see experimental methods). As
controls, I utilized BM-MSC-derived and GA-MSC-derived conditioned medium
(CM), BM-MSC-derived and GA-MSC-derived exosome-free conditioned medium
(EF-CM), and neural stem cell (NSC) medium alone (Figure 24). The cytokine
protein arrays for BM-MSC-derived and GA-MSC-derived exosomes demonstrate no
cytokines, which matches the profile seen for NSC medium alone. In contrast, BM61

Figure 23. MSC-derived exosomes do not contain growth factors.
Profiling of 33 growth factors and 8 growth factor receptors in exosomes
derived from BM-MSC and four GA-MSC lines. The growth factor profiles for
MSC-derived conditioned mediums and exosome-free conditioned mediums
are identical, and demonstrate the expression of numerous growth factors.
The growth factor profiles for MSC-derived exosomes is identical to the lysis
buffer plus resuspension medium (control), and do not demonstrate the
expression of any growth factors or growth factor receptors.
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Table 4. GA-MSC-derive exosomes do not contain major cytokines. Cytokine
immuno-blot array for 59 major cytokines and 1 major cytokine receptor.
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Figure 24. MSC-derived exosomes do not contain cytokines. Profiling of 59
cytokines and 1 cytokine receptor in exosomes derived from BM-MSC and four
GA-MSC lines. The cytokine profiles for MSC-derived conditioned mediums and
exosome-free conditioned mediums are identical, and demonstrate the
expression of several cytokine. The cytokine profiles for MSC-derived exosomes
is identical to the lysis buffer plus resuspension medium (control), and do not
demonstrate the expression of any cytokine or cytokine receptors.
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MSC-derived and GA-MSC-derived CM (which contains a low concentration of
exosomes), contained several cytokines, such as interleukin-6 (IL-6) and monocyte
chemo-attractant protein-1 (MCP-1), and has a similar profile as BM-MSC-derived
and GA-MSC-derived EF-CM after ultra-centrifuge extraction of exosomes.
Therefore, removing exosomes from BM-MSC-derived and GA-MSC-derived CM
does not alter the cytokine signatures, indicating that these cytokines are not present
within GA-MSC-derived exosomes.
MicroRNA Profiling of GA-MSC-Derived Exosomes
Exosomes are known to contain miRNA which, if present in GA-MSC-derived
exosomes, have the potential to alter GSC growth by regulating genes at the level of
transcription. Therefore, I utilized miRNA micro-array technology to analyze 2,019
miRNAs (miRBase 19.0) for their level of expression in GA-MSC-derived exosomes.
Specifically, BM-MSCs and GA-MSCs were cultured and total RNA was extracted
from isolated exosomes, as well as from the parental cell (see experimental
methods). The resulting miRNA profiles for GA-MSC-derived exosomes demonstrate
the presence of numerous miRNAs, distinctly different from that of the parental cell
line with p-values < 0.001 by paired student’s t-test (Figure 25). Interestingly, the
miRNA profiles for GA-MSC-derived exosomes were significantly different from each
other (p <0.001, one-way analysis of variance) (Figure 26). However, when
analyzed individually, the miRNA profiles between BM-MSC-derived exosomes and
GA-MSC-247-derived exosomes, as well as between GA-MSC-230-derived
exosomes and GA-MSC-247-derived exosomes, were not significantly different from
each other (p > 0.05, student’s t-test). Further analysis identified 37 miRNAs with an
average expression level of ≥ 5000 hybridization intensity (top 0.1%), among all
MSC-derived exosomes (Table 5), and were termed highly expressed miRNA.
Although the overall miRNA profiles were significantly different among the group of
MSC-derived exosomes, these highly expressed miRNA were consistent throughout
the group. This indicates that the presence of these specific miRNAs may be
conserved in all MSC-derived exosomes, and that any effects on GSC growth may
be linked to these highly expressed miRNAs.
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Figure 25. MSC-derived exosomes contain miRNA. (A/B) Profiling of
2,109 miRNA (miRBase 19.0) in BM-MSC and BM-MSC-derived exosomes.
BM-MSC-derived exosomes expressed a significantly different miRNA profile
compared to parental BM-MSC (p < 0.001, paired student’s t-test).
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Figure 25. MSC-derived exosomes contain miRNA. (C/D)
2,109 miRNA (miRBase 19.0) in GA-MSC 230 and GA-MSC
exosomes. GA-MSC 230-derived exosomes
expressed a
different miRNA profile compared to parental GA-MSC 230
paired student’s t-test).
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Figure 25. MSC-derived exosomes contain miRNA. (E/F) Profiling of
2,109 miRNA (miRBase 19.0) in GA-MSC 247 and GA-MSC 247-derived
exosomes. GA-MSC 247-derived exosomes expressed a significantly
different miRNA profile compared to parental GA-MSC 247 (p < 0.001,
paired student’s t-test).
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Figure 25. MSC-derived exosomes contain miRNA. (G/H)
2,109 miRNA (miRBase 19.0) in GA-MSC 262 and GA-MSC
exosomes. GA-MSC 262-derived exosomes
expressed a
different miRNA profile compared to parental GA-MSC 262
paired student’s t-test).
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Figure 25. MSC-derived exosomes contain miRNA. (I/J) Profiling of 2,109
miRNA (miRBase 19.0) in GA-MSC 20 and GA-MSC 20-derived exosomes.
GA-MSC 20-derived exosomes expressed a significantly different miRNA
profile compared to parental GA-MSC 20 (p < 0.001, paired student’s ttest).
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Figure 26. MicroRNA profiles of MSC-derived exosomes are different.
Graphical representation of the difference in miRNA expression, between
individual MSC-derived exosomes and the average miRNA expression for the
group, versus the difference in change expression of miRNA (between the
parental cell and exosome), between individual MSC-derived exosomes and
the average fold change for the group. The change in miRNA profile standard
deviation, between individual MSC-derived exosomes and the standard
deviation for the group, is denoted by sphere size. MicroRNA profiles for the
group of MSC-derived exosomes were significantly different from each other (p
< 0.01, ANOVA). Individual comparison of miRNA profiles between BM-MSCderived exosomes and GA-MSC 247-derived exosomes, as well as between
GA-MSC 230-derived exosomes and GA-MSC 247-derived exosomes, were
not significantly different from each other (p > 0.05, student’s t-test).
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Highly Expressed
miRNA

Mean
SD Above
Expression
the Mean
Level

hsa-miR-21-5p
hsa-miR-3960
hsa-miR-3665
hsa-miR-6089
hsa-miR-6087
hsa-miR-6090
hsa-miR-1246
hsa-miR-4497
hsa-miR-4668-5p
hsa-miR-4508
hsa-miR-6125
hsa-miR-1234-5p
hsa-miR-574-5p
hsa-let-7a-5p
hsa-miR-23a-3p
hsa-miR-4530
hsa-miR-4516
hsa-miR-23b-3p
hsa-miR-3613-3p
hsa-miR-4505
hsa-miR-574-3p
hsa-let-7c
hsa-miR-4787-5p
hsa-miR-638
hsa-let-7d-5p
hsa-miR-3656
hsa-let-7f-5p
hsa-miR-125b-5p
hsa-miR-3620-5p
hsa-let-7b-5p
hsa-miR-4492
hsa-miR-4507
hsa-miR-100-5p
hsa-miR-1587
hsa-miR-4484
hsa-miR-6085
hsa-miR-494

26,723
19,651
16,364
16,163
15,568
12,200
11,941
10,837
10,819
10,268
9,926
9,568
9,568
9,482
9,045
8,426
8,252
8,244
8,223
7,911
7,882
7,793
7,561
7,482
7,272
7,110
7,008
6,383
6,373
6,046
5,726
5,398
5,282
5,269
5,069
5,046
5,043

17.98
13.16
10.92
10.79
10.38
8.08
7.91
7.16
7.14
6.77
6.53
6.29
6.29
6.23
5.93
5.51
5.39
5.39
5.37
5.16
5.14
5.08
4.92
4.87
4.73
4.62
4.55
4.12
4.11
3.89
3.67
3.45
3.37
3.36
3.22
3.21
3.21

Table 5. MSC-derived exosomes contain highly expressed miRNA. MSCderived exosomes contain 37 miRNA with average expression levels greater
than 5000 hybridization intensity (> 3.0 standard deviations from the mean).
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2.3 Discussion
In this chapter I show that GA-MSCs release exosomes, and that the
production rate is dependent on both time in culture and cell-to-cell contact. I also
show that the BM-MSC-derived and GA-MSC-derived exosomes do not contain
significant amounts of growth factors or cytokines, but they do contain significant
amounts of miRNA, including a specific group of miRNA that is highly expressed.
MSC-derived exosomes have been confirmed by the use of both surface
markers, such as the tetraspanin proteins CD9 and CD81, as well as by electron
microscopy.32-33,164 A review of the most cited exosomal surface markers was
published by Mathivana, et al., and shows that the tetraspanin family proteins were
reliable markers for the detection of exosomes, as was the glycolytic enzyme
GAPDH.5 I show that GA-MSC-derived exosomes express both CD63 tetraspanin
protein and GAPDH exosomal markers. Additionally, as in the seminal paper on
exosome production by Trams, et al., I also visualized the characteristic morphology
exhibited by GA-MSC-derived exosomes by electron microscopy. Most importantly, I
was able to show by EM and immuno-gold staining that the CD63 surface marker
was an integral part of the exosomal membrane.15 These multiple lines of evidence
prove that GA-MSCs produce classical exosomes.
The rate at which exosomes are produced has, to this point, been assumed
constant, although exogenous factors such as time in culture and cell-to-cell contact
could have a significant impact. The effect of environmental factors such as hypoxia,
oxidative stress, and physical contact has been shown to affect the secretome
profile of secreted proteins of many cells types.165-167 Of these external factors,
hypoxia has been the most extensively studied not only in secretomics, but also in
the production of exosomes. For example, Ramteke, et al., demonstrated that
exosomes secreted under hypoxic conditions by prostate cancer cells, enhance cell
invasiveness and stemness, while Salomon, et al., showed that hypoxia-associated
exosomes released from placenta-derived MSCs, mediate endothelial cell migration
and blood vessel formation.168-169 Also, work by Park, et al., revealed that hypoxia
induced squamous cell carcinoma cells to produce exosomes capable of enhancing
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angiogenesis and metastasis, while King, et al., demonstrated that hypoxic
conditions mediated an increase in exosome secretion by breast cancer cells, and
that this effect was facilitated by HIF-1α.172-173 More relevant to my work,
Kucharzewska, et al., showed that GBM-derived exosomes modified endothelial
cells to improve tumor angiogenesis in a hypoxic environment.73 In addition to
hypoxic stress, other cellular stressors have also been implicated in influencing
exosome secretion. This can be seen in work by Hedlund, et al., in which thermal
and oxidative stress in leukemic T-cells and B-cells produces enhanced
immunosuppressive exosomes.174 These studies support the findings in which the
controlled environmental factors, time in culture and cell-to-cell contact, affect the
rate at which GA-MSC-derived exosomes are produced. To my knowledge this is the
first evidence describing the effects of external stressors on exosome production
rate, as the majority of research focuses on factors modifying exosomal content.
Along this line, further investigation into the effects of other cellular stressors, along
with paracrine signaling from neighboring GSCs, is necessary to gain a full
understanding of GA-MSC-derived exosomes.
Exosomes have been shown to contain a variety of proteins, however, the
use as a vehicle for delivering growth factors and cytokines is not well established.
However, there is an association between exosomes and both growth factors and
cytokines demonstrated in a variety of cell types. The content of exosomes can be
altered by activation of growth factor receptors on the parental cell, as demonstrated
by Genneback, et al., in which the treatment of cardiomyocytes with transforming
growth factor-beta (TGF-β) and/or platelet derived growth factor-BB (PDGF-BB)
resulted in cardiomyocyte-derived exosomes with significantly different mRNA
content.173 Conversely, exosomes can affect the expression of certain growth factor
and receptors in recipient cells, as shown by Lee, et al., in which BM-MSC-derived
exosomes down-regulate expression of vascular endothelial factor (VEGF) in breast
cancer cells.174 With respect to cytokines, Li and colleagues, show that stimulating
liver non-parenchymal cells (LNPCs) with interferon-alpha (IFN-α) results in LNPCderived exosomes with increased anti-hepatitis B virus (HBV) molecules, and Bretz,
et al., demonstrate that stimulation of monocytes with exosomes derived from
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malignant breast cancer ascites, induces the expression of interleukins -1-beta (IL1β), -6 (IL-6), and tumor necrosis factor-alpha (TNF-α).175-176 Furthermore, Huang, et
al., shows that dendritic cells-derived exosomes contain epidermal growth factor
(EGFR) in their membrane, and Hawari, et al, demonstrates that vascular
endothelial cell-derived exosomes harbor the tumor necrosis factor receptor (TNFR)
in their lipid bilayer, indicating the exosomal transfer of functional growth factor and
cytokine receptors.177-178 However, the packaging of these growth-promoting
proteins inside exosomes, instead of in the exosomal membrane, has to my
knowledge never been described. My results show the absence of a discrete set of
growth factors and cytokines within the intra-exosomal compartment of GA-MSCderived exosomes, which is logical given that the receptors for these proteins are
extracellular and signaling proteins would not be able to produce an effect while
trapped inside an exosome. To date, the only growth factor related cellular elements
found to be packaged in exosomes are mRNA for transforming growth fact-beta-1
(TGF-β1) and insulin-like growth factor-1 (IGF-1) in endothelial cell-derived
exosomes and BM-MSC-derived exosomes respectively, as described by Borges, et
al., and Tomasoni, et al.179-180 This results however, does not preclude the idea that
growth promoting proteins could be in the exosomal membranes. In fact, some
groups genetically modify exosomes to express certain growth factors and cytokines
on their surface to enable binding to the extracellular domain of receptors on the
recipient cell, in order to produce a desired effect. For example, Yu, et al., modified
dendritic cell-derived exosomes to express membrane bound transforming growth
fact-beta-1 (TGF-β1), while Zhang, et al., modified renal cancer cell-derived
exosomes to express membrane bound interleukin-12 (IL-12).181-182 The only known
exosomal membrane proteins shown to produce growth promoting effects, are
glycoproteins. Specifically, functional Wnt signaling proteins have been described in
exosomes from both fibroblasts and BM-MSCs.152,183 These membrane bound
proteins were not evaluated in my analysis of the classical and most well described
growth factors and cytokines, and further investigation into their presence in GAMSC-derived exosomes is warranted.
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Genetic material, such as DNA and RNA, have been extensively described in
the exosomes of many cell types. Therefore, it is reasonable that GA-MSC-derived
exosomes contain unique miRNA profiles. In addition to growth factor mRNA being
present in exosomes from endothelial and mesenchymal stem cells, other DNA and
RNA species are now accepted as classical exosomal constituents. Waldenstrom, et
al., found that cardiomyocyte-derived exosomes contain both DNA and RNA that
were functional in recipient fibroblasts.184 However, DNA and RNA are general terms
and include a variety of specific subtypes. In the realm of DNA species, Kahlert, et
al., described the presence of double-stranded DNA, including mutations in KRAS
and p53, in the exosomes derived from the serum of pancreatic cancer patients. 185
Additionally, the rare mitochondrial DNA (mtDNA) was discovered by Guescini, et
al., in exosomes derived from myoblasts, astrocytes and GBM cells. 70,186 With
regards to RNA, the presence of non-coding RNA species, such as miRNAs, are
more extensively described in exosomes than mRNA. MicroRNA has the potential to
produce longer lasting effects in recipient cells due its slow decay rate and the ability
to regulate multiple genes at the transcription level. In contrast mRNA influence is
relatively brief due to its faster decay rate as a result of translation into a protein.
Consistent with other cell types, I showed that the GA-MSC-derived exosomes
contained unique miRNA profiles as compared to the parental cell, including a
specific group of miRNA that were highly expressed. These results are further
supported by Wang, et al., Chen, et al., Koh, et al., and Xin, et al., who all described
a wide variety of both precursor and mature functional miRNA in exosomes derived
from BM-MSCs.153,187-189 However, given the nature of mRNA and their potential as
effectors on growth, the mRNA profiling of GA-MSC-derived exosomes is also
necessary in future work.
One of the weaknesses in these experiments was not obtaining a full
proteomic profile of GA-MSC-derived exosomes. Instead, I chose to focus on
profiling 41 major growth factors and receptors, and 60 major cytokines and
receptors. However, the list is not inclusive of all tumor-promoting proteins, and thus
a full proteomic analysis would have improved the analysis. Likewise, I did not
analyze the lipid component of GA-MSC-derived exosomes, which would be a more
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complete characterization. Furthermore, I only characterized the miRNA within GAMSC-derived exosomes, and did not evaluate other DNA or RNA species. Indeed,
mRNA could have a significant impact on recipient cells, when delivered via
exosomes. However, I chose to focus on miRNA due to their broad range of targets
and potential to alter gene expression at the level of transcription.
Conversely, one of the strengths of these experiments was the use of multiple
modalities to detect exosomes. Not only did I demonstrate GA-MSC-derived
exosome production by western blot, but I also confirmed production by electron
microscopy, immuno-gold labeling, and ELISA. Another strength of these
experiments was the characterization of GA-MSC-derived production under cellular
stress. This evaluation more accurately mimics the tumor microenvironment. The
last strength of the experiments was the full characterization of all known miRNAs.
Although many of the miRNAs have yet to be studied, this profiling provided a better
understanding of exosome content that is capable of altering gene expression.
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2.4 Conclusions
The results outlined in this chapter demonstrate for the first time the
production of exosomes by GA-MSCs. These GA-MSC-derived exosomes express
the accepted CD63 and GAPDH markers, and lack CD16 and CD32 non-exosomal
markers. Importantly, GA-MSC-derived exosomes are also within the established
40-100nm range, and possess the characteristic lipid bilayer membrane. Moreover,
the production of GA-MSC-derived exosomes varies with exposure to different levels
of cellular stressors. Additionally, GA-MSC-derived exosomes do not contain 41 of
the major growth factors, nor do they contain 60 of the major cytokines. However,
GA-MSC-derived exosomes contain numerous miRNAs, with distinct profiles
compared to the parental cell. Lastly, a specific group of miRNAs are highly
expressed in all GA-MSC-derived exosomes. These results prove that GA-MSCs are
capable of producing a varying amount of exosomes, depending on the
environmental conditions, whose internal content have the potential to impact
recipient cell biology.
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Chapter III
GA-MSC-Derived Exosomes
Increase GSC Tumorigenicity
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GA-MSC-Derived Exosomes Increase GSC Tumorigenicity

Proof that exosomes play a role in the communication between GA-MSCs
and GSCs requires demonstrating that GA-MSC-derived exosomes are taken up by
GSCs, and that these exosomes can modify the biology of GSCs. To my knowledge
this analysis has never been conducted in gliomas. Investigating the exosomal
interaction between cells of the tumor microenvironment may establish a new
intratumoral paracrine communication mechanism. Therefore, I hypothesized that
GA-MSC-derived exosomes can be internalized by GSCs and can increase the
tumorigenicity of GSCs. To test this hypothesis, I first established that GSCs are
capable of taking up GA-MSC-derived exosomes. These results proved that
intercellular exosomal interaction is feasible. I then showed that GSC proliferation
and clonogenicity is increased by GA-MSC-derived exosomes in vitro, and that GAMSC-derived exosomes increased the tumorigenicity of GSCs in vivo. These
findings established that GA-MSCs in the glioma microenvironment can alter the
growth and self-renewal of GSCs. Therefore, my studies indicate that GA-MSCs
communicate with GSCs via exosomes.
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3.1 Experimental Methods
GSC Internalization of GA-MSC-Derived Exosomes
In order to fluorescently label and track GA-MSC-derived exosomes, GAMSCs were transduced with a commercially available GFP-CD63 lentiviral construct
(System Biosciences), and expanded to 106 cells in MSC growth medium.
Transduced GA-MSCs were then washed and incubated for 48 hours in serum-free
NSC medium. GFP-labeled GA-MSC-derived exosomes were then isolated by
differential ultracentrifugation (see Chapter 2 Experimental Methods), added to GSC
cultures and allowed to incubate for 4 hours. Excess exosomes were subsequently
removed by PBS wash, and effective internalization of GA-MSC-derived exosomes
by GSCs was analyzed by fluorescent confocal microscopy.
Effects of GA-MSC-Derived Exosomes on GSC Proliferation
In order to isolate MSC-derived exosomes, BM-MSCs (Lonza, Inc.) and four
GA-MSC lines (Table 1) were expanded to 5.0 x 107 cells in MSC growth medium.
BM-MSCs and GA-MSCs were subsequently washed and incubated for 48 hours in
serum-free NSC medium. Likewise, to isolate GSC-derived self-exosomes, four
GSC lines (Table 2) were expanded to 1.0 x 107 cells in NSC growth medium. Both
MSC-derived and GSC-derived exosomes were then isolated from the conditioned
medium by differential ultracentrifugation and quantified by CD63 ELISA (see
Chapter 2 Experimental Methods), The remaining supernatant after exosome
extraction, exosome-free conditioned medium (EF-CM), was collected and utilized
as a control. Additionally, neurospheres from four GSC lines (Table 2) were
dissociated and placed in a 96 well plate at 2.5 x 103 cells/well. GSC-derived and
MSC-derived exosomes were then added to GSC cultures at doses of 5.0 x 104 and
1.0 x 105 exosomes/µL at time zero and at 48 hours, and incubated for a total period
of 96 hours. GSCs were also treated with NSC medium and GA-MSC-derived EFCM. After 96 hours in culture, GSCs were assessed for viability using a colorimetric
assay (water-soluble tetrazolium [WST-1], Roche), and the absorbance measured at
450nm. Absorbance of GSCs treated with MSC-derived exosomes was compared to
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that of untreated GSC controls. All experiments were performed in quadruplicate and
statistical analysis was performed utilizing the paired student’s t-test.
Effects of GA-MSC-Derived Exosomes on GSC Clonogenicity
In order to isolate MSC-derived exosomes, BM-MSCs (Lonza, Inc.) and four
GA-MSC lines (Table 1) were expanded to 5.0 x 107 cells in MSC growth medium.
BM-MSCs and GA-MSCs were subsequently washed and incubated for 48 hours in
serum-free NSC medium. Likewise, to isolate GSC-derived self-exosomes, four
GSC lines (Table 2) were expanded to 1.0 x 107 cells in NSC growth medium. Both
MSC-derived and GSC-derived exosomes were then isolated from the conditioned
mediums by differential ultracentrifugation and quantified by CD63 ELISA (see
Chapter 2 Experimental Methods), The remaining supernatant after exosome
extraction, exosome-free conditioned medium (EF-CM), was collected and utilized
as a control. GSC-derived and MSC-derived exosomes were then added to singlecell suspensions of four GSC lines (Table 2) in 96-well plates at a dose of 4.0 x 102
exosomes/µL at time zero, and at 1 week and 2 week time points. GSCs were also
treated with NSC medium and GA-MSC-derived EF-CM. After 3 weeks of culture,
quantification of GSC neurospheres was performed. Neurosphere formation of
GSCs treated with GA-MSC-derived exosomes was compared to that of untreated
GSC controls. All experiments were performed in quadruplicate and statistical
analysis was performed utilizing the paired student’s t-test.
Effects of GA-MSC-Derived Exosomes on GSC Tumorigenicity
In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20
were expanded to 5.0 x 107 cells in MSC growth medium. GA-MSCs were
subsequently washed and incubated for 48 hours in serum-free NSC medium.
Likewise, to isolate GSC-derived self-exosomes, GSC 262 and GSC 20 (matching
pairs) were expanded to 1.0 x 107 cells in NSC growth medium. Both MSC-derived
and GSC-derived exosomes were then isolated from the conditioned mediums by
differential ultracentrifugation and quantified by CD63 ELISA (see Chapter 2
Experimental Methods), The remaining supernatant after exosome extraction,
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exosome-free conditioned medium (EF-CM), was collected and utilized as a control.
Additionally, GSC 262 and GSC 20 were expanded to 3.0 x 107 cells in preparation
for pre-treatment and implantation. GSC-derived and GA-MSC-derived exosomes
were then added to GSC cultures at a dose of 1.0 x 109 exosomes/mL. GSCs were
also pre-treated with NSC medium and GA-MSC-derived EF-CM. After 96 hours of
pre-treatment, excess exosomes were eliminated by PBS wash, and GSC
neurospheres were dissociated. GSCs were then injected into the right frontal lobe
of nude mice (n=15/group, 5.0 x 105 cells/mouse), utilizing a cranial bolt-guided,
stereotactic system. A cohort of mice (n=9) were followed until moribund and then
sacrificed. Another cohort of mice (n=6) were sacrificed at 20 and 40 days post
implantation. After sacrifice, mouse brains were removed, embedded in paraffin, and
sectioned tumors. Tumor volumes and survival results of the GSCs treated with GAMSC-derived exosomes were compared to untreated GSC controls. Tumor volumes
were calculated by adding multiple cross-sectional areas through the tumors after
H&E staining of histologic sections. Statistical analysis was performed utilizing the
paired student’s t-test for tumor volume analysis, and log-rank (Mantel-Cox) test for
survival analysis.
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3.2 Results
GSCs Internalize GA-MSC-derived exosomes
To confirm the localization of MSC-derived exosomes to the cytoplasm of
GSCs, we labeled exosomes using a CD63-green fluorescent fusion protein. The
robustness of the CD63 marker in GA-MSC-derived exosomes allowed the use of
this CD63-GFP fusion protein for tracking. Additionally, I exploited the optical
sectioning capabilities of fluorescent confocal microscopy for tracking of GA-MSCderived exosomes, instead of fluorescent light microscopy. In these experiments,
CD63-GFP expressing GA-MSCs were cultured, and GFP labeled exosomes were
isolated and co-cultured with GSCs (see experimental methods). After 4 hours of coculturing, fluorescent confocal microscopy revealed the presence of GFP-labeled
GA-MSC-derived exosomes exclusively in the cytoplasm of GSCs, and not in the
nucleus (Figure 27). Furthermore, GFP-labeled exosomes appeared to be grouped
together within the cytoplasm of GSCs. Taken together, these results indicate that
GA-MSC-derived exosomes can be internalized by GSCs.
GA-MSC-Derived Exosomes Increase GSC Proliferation
To determine the growth effects of MSC-derived exosomes on GSCs, I
conducted in vitro co-culture experiments in which I assayed GSC proliferation after
exposure to GA-MSC-derived exosomes. Specifically, GSCs and MSC were
cultured, and exosomes isolated and co-cultured with GSCs (see experimental
methods). Proliferation assays demonstrate that GA-MSC-derived exosomes
significantly increased (p < 0.01, paired student’s t-test) the proliferation of GSCs in
a dose dependent manner (Figure 28). Importantly, the exosome-mediated
promotion of growth in GSCs was significant with the treatment of exosomes derived
from the matching GA-MSCs isolated from the same tumor specimen. Likewise, BMMSC-derived exosomes also exerted growth-promoting effects on each GSC.
However, in general the proliferation effects of the GA-MSC-derived exosomes were
greater than that of BM-MSC-derived exosomes. As expected, and consistent with
earlier results, treatment of GSCs with GA-MSC-derived EF-CM, also significantly
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A

B

Figure 27. GSCs internalize fluorescently
labeled MSC-derived exosomes. (A/B)
Fluorescent
confocal
microscopy
demonstrating the internalization of GFPCD63 labeled BM-MSC-derived exosomes
by GSC 262 and GSC 20, respectively.
Fluorescently labeled exosomes (green) are
localized to the cytoplasm of GSCs and are
excluded from the nucleus (DAPI stained
blue).
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (A) Proliferation assay for GSC
11 demonstrating a significant increase (p < 0.01, student’s t-test) in viability with the treatment of
GA-MSC 230-derived exosomes at two doses. As expected, treatment of GSC 11 with GA-MSC 230derived exosome-free conditioned medium significantly increases viability, while treatment with GSC
11-derived self-exosomes does not have a significant effect. (B) Proliferation assay for GSC 11
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with
treatment of exosomes derived from BM-MSC and three
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (C) Proliferation assay for GSC
7-2 demonstrating a significant increase (p < 0.01, student’s t-test) in viability with the treatment of GAMSC 247-derived exosomes at two doses. As expected, treatment of GSC 7-2 with GA-MSC 247derived exosome-free conditioned medium significantly increases viability, while treatment with GSC 72-derived self-exosomes does not have a significant effect. (D) Proliferation assay for GSC 7-2
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with
treatment of exosomes derived from BM-MSC and three
GA-MSC lines.
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (E) Proliferation assay for GSC
262 demonstrating a significant increase (p < 0.01, student’s t-test) in viability with the treatment of GAMSC 262-derived exosomes at two doses. As expected, treatment of GSC 262 with GA-MSC 262derived exosome-free conditioned medium significantly increases viability, while treatment with GSC
262-derived self-exosomes does not have a significant effect. (F) Proliferation assay for GSC 262
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with
treatment of exosomes derived from BM-MSC and three
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (G) Proliferation assay for
GSC 20 demonstrating a significant increase (p < 0.01, student’s t-test) in viability with the treatment
of GA-MSC 20-derived exosomes at two doses. As expected, treatment of GSC 20 with GA-MSC 20derived exosome-free conditioned medium significantly increases viability, while treatment with GSC
20-derived self-exosomes does not have a significant effect. (H) Proliferation assay for GSC 20
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with
treatment of exosomes derived from BM-MSC and 89
three GA-MSC lines.

increased GSC proliferation compared with untreated controls (p < 0.01, paired
student’s t-test). In contrast, treatment of GSCs with GSC-derived self-exosomes,
did not have a significant effect on GSC proliferation (p > 0.05, paired student’s ttest). This finding confirms previous reports that exosomes are recycled and do not
exert any known autocrine effects on the cell from which they are derived, as GSCderived self-exosomes had no effect on GSCs.190 These results indicate that
exosome-mediated growth effects are dependent on the cell-of-origin, and that BMMSC-derived and GA-MSC-derived exosomes increase the proliferation of GSCs.
GA-MSC-Derived Exosomes Increase GSC Clonogenicity
I then evaluated the effects of MSC-derived exosomes on the ability of GSCs
to self-replicate, by conducting in vitro co-culture experiments in which I assayed
GSC clonogenicity after exposure to GA-MSC-derived exosomes. Specifically,
GSCs and MSC were cultured, and exosomes isolated and co-cultured with GSCs
(see experimental methods). Clonogenicity assays demonstrate that GA-MSCderived exosomes significantly increased GSC neurosphere formation and thus
clonogenicity (p < 0.05, paired student’s t-test) (Figure 29). Importantly, the
exosome-mediated promotion of self-renewal in GSCs was significant with the
treatment of exosomes derived from the matching GA-MSCs isolated from the same
tumor specimen Likewise, BM-MSC-derived exosomes also increased GSC
clongenicity. As expected, treatment of GSCs with GA-MSC-derived EF-CM also
increased GSC clonogenicity (p < 0.05, paired student’s t-test). In contrast, and in
agreement with the proliferation results, treatment of GSCs with GSC-derived selfexosomes did not have a significant effect on GSC clonogenicity (p > 0.05, paired
student’s t-test). These results indicate that BM-MSC-derived and GA-MSC-derived
exosomes enhance the clonogenicity of GSCs.
GA-MSC-Derived Exosomes Enhance GSC Tumorigenicity
I next sought to determine whether the in vitro results also occurred in vivo.
To assess the effects of GA-MSC-derived exosomes on GSCs in vivo, I utilized GSC
xenografts in nude mice. Specifically, GSCs and MSC were cultured, and exosomes
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (A) Clonogenic assay for GSC
11 demonstrating a significant increase (p < 0.01, student’s t-test) in self-renewal with the treatment of
GA-MSC 230-derived exosomes. As expected, treatment of GSC 11 with GA-MSC 230-derived
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 11derived self-exosomes does not have a significant effect. (B) Clonogenic assay for GSC 11
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of
exosomes derived from BM-MSC and three GA-MSC91
lines.
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (C) Clonogenic assay for GSC
7-2 demonstrating a significant increase (p < 0.01, student’s t-test) in self-renewal with the treatment of
GA-MSC 247-derived exosomes. As expected, treatment of GSC 7-2 with GA-MSC 247-derived
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 7-2derived self-exosomes does not have a significant effect. (D) Clonogenic assay for GSC 7-2
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of
exosomes derived from BM-MSC and three GA-MSC92
lines.
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (E) Clonogenic assay for GSC
262 demonstrating a significant increase (p < 0.01, student’s t-test) in self-renewal with the treatment
of GA-MSC 262-derived exosomes. As expected, treatment of GSC 262 with GA-MSC 262-derived
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 262derived self-exosomes does not have a significant effect. (F) Clonogenic assay for GSC 262
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of
exosomes derived from BM-MSC and three GA-MSC93lines.
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (G) Clonogenic assay for GSC
20 demonstrating a significant increase (p < 0.01, student’s t-test) in self-renewal with the treatment of
GA-MSC 20-derived exosomes. As expected, treatment of GSC 20 with GA-MSC 20-derived
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 20derived self-exosomes does not have a significant effect. (H) Clonogenic assay for GSC 20
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of
exosomes derived from BM-MSC and three GA-MSC94lines.

isolated and co-cultured with GSCs (see experimental methods). In vivo experiments
demonstrated that pre-treatment of GSC 262 with GA-MSC 262-derived exosomes
significantly decreased median survival from 56 to 45 days (p < 0.05, log-rank test)
(Figure30). Furthermore, pre-treatment of GSC 20 with GA-MSC 20-derived
exosomes significantly decreased median survival from 49 to 37 days (p < 0.05, logrank test) (Figure 30). Additionally, in agreement with in vitro results, pre-treatment
of GSC xenografts with GA-MSC-derived EF-CM also significantly decreased
median survival (p < 0.05, log-rank test), while pre-treatment of GSCs with GSCderived self-exosomes did not have a significant effect on median survival (p > 0.05,
log-rank test).
Histologic analysis of brain specimens from mice implanted with GSC 262
pre-treated with GA-MSC 262-derived exosomes, demonstrated a significant
increase in tumor volume when compared to untreated GSC controls at 40 days
post-implantation, and not at 20 days post-implantation (p < 0.01, paired student’s ttest) (Figure 31 and Figure 32). Similarly, histologic analysis of brain specimens
from mice implanted with GSC 20 pre-treated with GA-MSC 20-derived exosomes,
demonstrated a significant increase in tumor volume when compared to untreated
GSC controls at both 20 and 40 days post-implantation (p < 0.01, paired student’s ttest) (Figure 31 and Figure 32). As expected, pre-treatment of GSCs with GA-MSCderived EF-CM also significantly increased tumor volume at 20 and 40 days postimplantation (p < 0.05, paired student’s t-test). In contrast, and in agreement with in
vitro results, treatment of GSCs with GSC-derived self-exosomes did not have a
significant effect on tumor volume at 20 and 40 days post-implantation (p > 0.05,
paired student’s t-test). These histologic results corroborate with survival data and
findings from in vitro experiments. Together, these results indicate that GA-MSCderived exosomes significantly increase the tumorigenicity of GSCs.
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Figure 30. GA-MSC-derived exosomes decrease median
survival. (A) Survival curve for mice with GSC 262 xenogafts,
demonstrating a significant decrease (p < 0.05, log-rank test) in
median survival from 56 to 45 days with pre-treatment of GAMSC 262-derived exosomes. (B) Survival curve for mice with
GSC 20 xenogafts, demonstrating a significant decrease (p <
0.05, log-rank test) in median survival from 49 to 37 days with
pre-treatment of GA-MSC 20-derived exosomes.
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Figure 31. GA-MSC-derived exosomes increase tumor burden (20 days).
(A/B) H&E staining and tumor volumes for GSC 262 xenografts 20 days postimplantation, demonstrating no significant difference in tumor burden between the
untreated GSC 262 control group, and GSC 262 treated with GA-MSC 262-derived
self exosomes.
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Figure 31. GA-MSC-derived exosomes increase tumor burden (20 days).
(C/D) H&E staining and tumor volumes for GSC 20 xenografts 20 days postimplantation, demonstrating no significant difference in tumor burden between the
untreated GSC 20 control group, and GSC 20 treated with GA-MSC 20-derived
self exosomes.
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Figure 32. GA-MSC-derived exosomes increase tumor burden (40 days).
(E/F) H&E staining and tumor volumes for GSC 262 xenografts 40 days postimplantation, demonstrating a significant difference in tumor burden between the
untreated GSC 262 control group, and GSC 262 treated with GA-MSC 262derived self exosomes.
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Figure 32. GA-MSC-derived exosomes increase tumor burden (40 days).
(GH) H&E staining and tumor volumes for GSC 262 xenografts 20 days postimplantation, demonstrating no significant difference in tumor burden between the
untreated GSC 20 control group, and GSC 20 treated with GA-MSC 20-derived
self exosomes.
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3.3 Discussion
In this chapter I show for the first time that GA-MSC-derived exosomes are
taken up by GSCs, and that these exosomes increase proliferation and clonogenicity
of GSCs in vitro, as well as increase tumorigenicity of GSCs in vivo.
Paracrine communication between cells of the tumor stromal cells and tumor
propagating cells is well described, and recent studies have implicated exosomes as
part of this system.190-191 The majority of the literature focuses on the uptake and
utilization of cancer stem cell-derived exosomes by the surrounding stromal cells of
the microenvironment, although evidence supporting the internalization and usage of
stromal-derived exosomes by cancer stem cells is mounting.77-78,125-126 For example,
Ekstrom, et al., showed that monocyte-derived exosomes, labeled with the
fluorescent membrane dye PKH67, were taken up by MSCs into their cytoplasm,
while Bijnsdorp, et al., revealed that prostate epithelial cells endocytosed PKH67labeled colorectal cancer-derived exosomes.192-193 More related to my research in
gliomas, Skog, et al., demonstrated that GBM-derived PKH67-labeled exosomes,
were internalized by brain microvascular endothelial cells. 80 These studies support
the findings that fluorescent labeled exosomes can be visualized either attached to
the membrane of within the cytoplasm of recipient cells. However, the tendency of
this fluorescent dye, as with other lipophilic dyes, to leak out of the membrane and
into surrounding cells suggests that they are not ideal for the labeling of exosomes.
To overcome the inadequacy of fluorescently labeling exosomes with the
PKH67 membrane dye, other approaches were investigated. Evidence of a more
reliable method for fluorescently labeling exosomes was first published by Wei, et
al., who showed that lung cancer cell-derived exosomes could be labeled with a
CD63-GFP fusion protein.194 This method was then utilized by Suetsugu, et al., who
demonstrated that CD63-labeled exosomes from breast cancer cells were taken up
by normal lung tissue cells.195 These two articles support the findings that GA-MSCderived exosomes can be more precisely labeled with the CD63-GFP fusion protein,
and that GA-MSC-derived exosomes can be more clearly tracked intracellularly in
recipient GSCs to demonstrate internalization.
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Although there are multiple studies exploring the intercellular communication
between stromal cells and CSCs, few studies have investigated the role of stromal
cell-derived exosomes in interactions with CSCs. Previous studies have indicated
that stromal cell-derived exosomes can enhance the growth of CSCs in other cancer
types, thereby supporting the results of my study. For example, Luga, et al., found
that exosomes from breast cancer associated fibroblasts (CAFs) enhance the
growth and metastasis of breast cancer cells via activation of the Wnt signaling
pathway.125 Similarly, Zhu, et al., showed that BM-MSC-derived exosomes
increased the tumorigenicity of gastric carcinoma and colon cancer cells via the
ERK1/2 signaling pathway.155 Similarly, Roccaro, et al., reported that BM-MSC
derived exosomes from patients with multiple myeloma, enhanced progression of
multiple myeloma tumors via delivery of oncogenic proteins that affected cell
adhesion and migration.154 Consistent with these reports, I show that BM-MSCderived exosomes promote the growth of CSCs in gliomas. My findings expand on
the results of these studies by also showing that exosomes derived from a bona fide
cell in the tumor microenvironment, GA-MSCs, also increase the growth of CSCs in
gliomas. Furthermore, I also demonstrated that MSC-derived exosomes also
increase the clonogenicity of CSCs in glioma, which was not investigated in these
studies. Interestingly, GA-MSC-derived exosomes appeared to have more potent
effects on GSC growth than BM-MSC-derived exosomes, suggesting that residence
within the glioma niche enhances the growth promoting ability of MSCs. Therefore,
to my knowledge, this is the first study to examine specifically the function of tumorderived MSCs on CSC growth and self-renewal.
Interestingly, Roccaro, et al., also found that BM-MSC-derived exosomes
from normal subjects without multiple myeloma, had an inhibiting effect on CSCs.154
My experimental results did not indicate a tumor-inhibiting function of BM-MSCderived exosomes, as described by Roccaro and colleagues.154 Instead, BM-MSCderived exosomes from normal subjects caused similar growth-promoting effects in
GSCs as GA-MSC-derived exosomes. Nevertheless, these results define a gliomapromoting role of GA-MSC-derived exosomes and are supported by the literature.
Furthermore, since we previously described the glioma-promoting properties of GA102

MSCs co-cultured with GSCs, it was not surprising that the exosomes released by
GA-MSCs were also tumor-promoting in nature, and not tumor-inhibiting.97 It is
unclear why the experimental results of Roccaro, et al, differ from my investigation,
however it is reasonable to consider that the role of BM-MSCs in multiple myeloma,
a tumor of the bone, may be different from their role in other cancers.
To my knowledge, there are no studies describing a tumor-inhibiting role of
stroma-derived exosomes. Instead, researchers are utilizing the robust functionality
of the stroma-derived exosome system as a vector to deliver anti-tumor therapies.74,
196

The reasoning behind this therapeutic approach, is that the tumor-promoting

properties of modified stroma-derived exosomes are masked or overcome by the
anti-tumor properties imparted by the therapeutic molecules. In any case, the
enhancement of tumors by stroma-derived exosomes is being evaluated
mechanistically in a variety of cancer types. Thus, these findings necessitate future
investigation into the mechanism responsible for the glioma-promoting effects of GAMSC-derived exosomes.
One of the weaknesses of this study was not conducting a time course
experiment involving the tracking of fluorescently labeled GA-MSC-derived
exosomes. This would have allowed the visualization of the exosome internalization
process by GSCs, thus providing better insight and understanding of this intercellular
communication pathway. Another weakness was not performing a limiting dilution for
the study of clonogenicity in vivo. This experiment would involve implanting fewer
and fewer GSCs pre-treated with GA-MSC-derived exosomes, in order to determine
the least amount of cells that can form a tumor. Results from this experimental
method would yield in vivo proof of clonogenic enhancement in GSCs, whereas
tumor burden yields in vivo proof of only proliferative enhancement. Nevertheless, I
did study, and show increases in, GSC growth and tumorigenicity in vivo.
Conversely, one of the strengths of this study was the use of matched pairs of
GSCs and GA-MSCs that were isolated from the same patient tumor specimen. To
my knowledge the use of such pairs in glioma studies is unique and has never been
incorporated in research studies. This novel approach ensures that I investigated the
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communication between cells actually present in the tumor niche, rather than
utilizing commercially available BM-MSCs or the U87 glioblastoma cell line.
However, I did utilize BM-MSCs in order to demonstrate the tumor-promoting
function of MSC-derived exosomes in general. Another strength was the use of
GSCs treated with GA-MSC-derived exosome-free conditioned medium as a positive
control in demonstrating increases in GSC growth and self-renewal. Normal GAMSC-derived conditioned medium contains a low concentration of exosomes, and
therefore should not be used as a control. Furthermore, I utilized GSCs treated with
GSC-derived self-exosomes as a negative control to demonstrate that the tumorpromoting properties are not universal to all exosomes, but are specific to the cell of
origin. The last strength of this study was pre-treating GSCs with GA-MSCs in
culture before in vivo implantation. Since I was investigating the exosomal
communication between GA-MSCs and GSCs, this pre-treatment protocol ensured
that GA-MSC-derived exosomes only interacted with GSCs. Conversely, co-injection
of GSC and GA-MSC-derived exosomes would allow for exosomes to interact with
other cells in the tumor niche.
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3.4 Conclusions
The results of this investigation demonstrate for the first time that GA-MSCderived exosomes can be tracked utilizing both fluorescent membranes dye and
GFP-CD63 fusion protein. Furthermore, GSCs can internalize and organize GAMSC-derived exosomes intracellularly. Most importantly I demonstrate that GAMSC-derived exosomes significantly increase the proliferation of GSCs in vitro in a
dose dependent manner. Additionally, GA-MSC-derived exosomes can also
increase neurosphere formation, and thus clonogenicity, of GSCs in vitro. Moreover,
GA-MSC-derived exosomes significantly increase the tumorigenicity of GSCs in
vivo, thereby increasing tumor burden and decreasing median survival. These
results prove that GA-MSC-derived exosomes alter the biology of GSCs.
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Chapter IV
MicroRNA in GA-MSC-Derived Exosomes
Promote Glioma Growth
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MicroRNA in GA-MSC-Derived Exosomes Promote Glioma Growth

Evidence that GA-MSCs promote the growth of gliomas via exosomal miRNA
requires identification of oncogenic miRNAs in GA-MSC-derived exosomes and
demonstration that the miRNAs are functional in GSCs. To my knowledge such an
analysis has never been conducted in gliomas. By investigating the role of exosomal
miRNAs in the evolution of glioma, I hope to define a new intratumoral paracrine
communication system. Therefore, I hypothesized that miRNA delivered via GAMSC-derived exosomes increase the tumorigenicity of GSCs. To test this
hypothesis, I first identified a specific group of miRNAs which were both highly
expressed and highly enriched in GA-MSC-derived exosomes. I then compared
expression levels for predicted gene targets of this group of exosomal miRNAs in
untreated GSCs with those in GSCs after treatment with GA-MSC-derived
exosomes. These results established a functional connection between miRNAs in
GA-MSC-derived exosomes and recipient GSCs. I then showed that the growth and
self-renewal of GSCs are increased by over-expression of these exosomal miRNAs
in GSCs in vitro. These findings established that GA-MSCs alter the proliferation and
clonogenicity of GSCs by secreting exosomes carrying specific miRNA. In the future,
I aim to demonstrate that miRNA in GA-MSC-derived exosomes increase the
tumorigenicity of GSCs in vivo.
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4.1 Experimental Methods
Identification of Key MicroRNAs in GA-MSC-Derived Exosomes
In order to identify miRNAs that were not only highly expressed in MSCderived exosomes (Table 5), but also highly enriched, I utilized the miRNA profiles
obtained from earlier experiments (see Chapter 2 Experimental Methods). Out of the
2,019 miRNA analyzed, I identified a sub-population of miRNA that had significantly
different average levels of expression between the MSC-derived exosomes and the
parental cell (p < 0.05, paired student’s t-test). This sub-population was termed
enriched in MSC-derived exosomes. The change in expression for each enriched
miRNA was then calculated by taking the difference in average expression levels
between the MSC-derived exosome and the parental cell. MicroRNA that had
expression changes greater than 2 standard deviations from the mean (top 2.5%)
were termed highly enriched miRNA.
In order to identify miRNA in the enriched subpopulation that were also the
most highly expressed in MSC-derived exosomes, an expression-to-enrichment ratio
(E:R ratio) was calculated, by multiplying the change in expression between the
exosome and the parental cell, by the ratio of expression levels between the
exosome and the parental cell.
E:R ratio = (Exosome – Cell) x (Exosome / Cell)
The E:R ratio yielded two groups of miRNAs at the extremes of the
distribution. One group of miRNA was both highly expressed and highly enriched in
MSC-derived exosomes when compared to the MSC parental cell. Another group of
miRNA was both highly expressed and highly enriched in parental MSCs, and thus
had low expression and was depleted from MSC-derived exosomes.
Identification of Nucleotide Motifs in Exosome Enriched and Depleted MicroRNA
In order to determine if specific nucleotide motifs in miRNA correlate with
preferential packaging into exosomes, pre-miRNA (stem-loop) and mature miRNA
sequences were obtained from the miRBase database for the highly enriched and
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highly expressed miRNA in MSC-derived exosomes.197 Pre-miRNA and maturemiRNA sequences were initially analyzed for their degree of guanine-cytosine to
uracil-adenine (G-C:U-A) ratio. Additionally, pre-miRNA and mature-miRNA
sequences were evaluated to identify specific sub-sequences that were common
among the highly expressed and highly enriched miRNA groups. Statistical analysis
was performed utilizing the paired student’s t-test.
Gene Expression Profiling of GSCs Treated with GA-MSC-Derived Exosomes
In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20
were expanded to 5.0 x 106 cells in MSC growth medium. GA-MSCs were
subsequently washed and incubated for 48 hours in serum-free NSC medium. GAMSC-derived exosomes were then isolated from the conditioned mediums by
differential ultracentrifugation and quantified by CD63 ELISA (see Chapter 2
Experimental Methods). GA-MSC-derived exosomes were then added to GSC
cultures (1.0 x 109 exosomes/mL). GSCs were also treated with NSC medium as a
control. After 48 hours of treatment, excess exosomes were removed by PBS wash,
and total RNA was isolated from both groups of GSCs (see Chapter 2 Experimental
Methods). Total RNA from both groups of GSCs was then analyzed for gene
expression profiling utilizing Illumina next-generation sequencing technology,
through LC Sciences. Gene expression profiles from untreated GSCs and GSCs
after treatment with GA-MSC-derived exosomes were statistically compared by
paired student’s t-test.
Gene Target Analysis of Exosome Enriched and Depleted MicroRNA
I identified predicted gene targets for the 8 highly enriched and highly
expressed miRNA in MSC-derived exosomes, utilizing the miRTarget 2.0 database
(> 80 target score).198 I then assessed the expression level of the predicted gene
targets for the 8 highly expressed and highly enriched miRNA in GSCs after
treatment with GA-MSC-derived exosomes, by querying the relative gene
expression profile. Specifically, the level of expression for a given miRNA gene
target in untreated GSCs controls was compared to that of GSCs treated with GA109

MSC-derived exosomes. This analysis yielded an average fold change for each
predicted gene target of the 8 highly expressed and highly enriched miRNA. By the
same method, I also performed analysis for the predicted gene targets of the 8
miRNA that are depleted from GA-MSC-derived exosomes. The average fold
change among the predicted gene targets for highly enriched and highly expressed
miRNA in GA-MSC-derived exosomes, was then compared to that of the depleted
miRNA by performing un-paired student’s t-test.
Over-Expression of MicroRNAs in GSCs
To test the effects of highly expressed and highly enriched exosomal miRNA
on GSCs, each miRNA was over-expressed in GSCs by lentiviral (LV) transduction.
Initially, plasmids of LV-GFP-miRNA constructs for each specific miRNA, as well as
LV-GFP-miRNA-scramble construct (control), were isolated from expanded bacterial
stocks (Qiagen) using a plasmid maxi kit (Qiagen). Lentiviral vectors were generated
by transfecting human embryonic kidney 293FT (HEK-293FT) cells with individual
miRNA plasmids, along with a viral packaging plasmid and a viral envelope plasmid.
Resulting lentiviral (LV) vectors were isolated by ultracentrifugation of conditioned
medium from HEK-293 cells. Viral titers were then calculated by inoculation of HEK293 cells with limiting dilutions of complete LV-GFP-miRNA viral vectors, and
assessing for GFP expression. Each LV-GFP-miRNA viral vector was then
transduced in GSC 262 and GSC 20 (1.0 x 10

6

cells) at a multiplicity of infection

(MOI) of 3, and cultured under puromycin selection (1nM) for 72 hours. Integration of
the GFP-miRNA construct was assessed by fluorescent light microscopy. RNA was
then isolated from each of the GFP-miRNA transduced cell lines (see Chapter 2
Experimental Methods) for verification of miRNA over-expression by qRT-PCR.
Additionally, RNA was also isolated from GSCs treated with NSC medium, as well
as from GSCs treated with GA-MSC-derived exosomes for a period of 48 hours. The
level of miRNA expression determined by qRT-PCR for the GFP-miRNA expressing
GSCs was then compared to that of untreated GSC controls and GSCs after
treatment with GA-MSC-derived exosomes. Statistical analysis was performed
utilizing paired student’s t-test.
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Functional Verification of Over-Expressed miRNA in GSCs
GSCs stably expressing the GFP-miR construct were expanded to 106 cells,
and protein isolated by the addition of cell lysis buffer (see Chapter 2 Experimental
Methods). Additionally, GSCs were expanded to 1.0 x 106 cells and treated with NSC
medium, GA-MSC-derived exosomes (1.0 x 109 exosomes/mL), and GA-MSCderived exosomes plus anti-miRNA (Qiagen) at 1nM. After 48 hours of culture,
excess exosomes were removed by PBS wash, and protein was isolated by the
addition of cell lysis buffer (see Chapter 2 Experimental Methods). Specific predicted
gene targets for each over-expressed miRNA were then assessed for degree of
down-regulation by western blot analysis. Results were compared with the degree of
miRNA gene target expression in GSCs after treatment with NSC medium, after
treatment with GA-MSC-derived exosomes, and after treatment with GA-MSCderived exosomes plus anti-miR inhibitors (Qiagen) at 1nM.
Effects of Exosomal MicroRNAs on GSC Proliferation
In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20
were expanded to 5.0 x 106 cells in MSC growth medium. GA-MSCs were
subsequently washed and incubated for 48 hours in serum-free NSC medium. MSCderived and GSC-derived exosomes were then isolated from the conditioned
mediums by differential ultracentrifugation and quantified by CD63 ELISA (see
Chapter 2 Experimental Methods). GSC 262 and GSC 20 were then placed in 16
wells of a 96-well plate (2.5 x 103 cells/well). Four the wells were treated with NSC
medium. Another four wells were treated with GA-MSC-derived exosomes (1.0 x 104
exosomes/µL). Another four wells were treated with GA-MSC-derived exosomes (1.0
x 104 exosomes/µL) plus anti-miRNA (Qiagen) by lipofection at 1nM. The last four
wells were treated with anti-miRNA (Qiagen) by lipofection at 1nM. Additionally,
neurospheres from GSCs expressing the GFP-miRNA constructs were dissociated
and placed into another four wells of the 96-well plate (2.5 x 103 cells/well). Finally,
neurospheres of GSCs expressing the GFP-miRNA-scramble construct (control)
were placed into another four wells of the 96-well plate (2.5 x 103 cells/well). After 96
hours of incubation, GSC viability was assessed using a colorimetric assay WST-1
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(Roche), and the absorbance measured at 450nm. The absorbance for each
experimental treatment group of GSCs was compared to that of untreated GSC
controls, as well as to that of GSCs expressing the GFP-miRNA-scramble construct.
All experiments were performed in quadruplicate and statistical analysis was
performed utilizing the paired student’s t-test.
Effects of Exosomal MicroRNAs on GSC Clonogenicity
In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20
were expanded to 5.0 x 106 cells in MSC growth medium. GA-MSCs were
subsequently washed and incubated for 48 hours in serum-free NSC medium. MSCderived and GSC-derived exosomes were then isolated from the conditioned
mediums by differential ultracentrifugation and quantified by CD63 ELISA (see
Chapter 2 Experimental Methods). Neurospheres from GSC 262 and GSC 20 were
then dissociated and placed into single cell suspensions in each well of four 96-well
plates. One 96-well plate was treated with NSC medium. Another 96-well plate was
treated with GA-MSC-derived exosomes (4.0 x 102 exosomes/µL). Another 96-well
plate was treated with GA-MSC-derived exosomes (4.0 x 102 exosomes/µL) plus
anti-miRNA (Qiagen) by lipofection at 1nM. The last 96-well plate was treated with
anti-miRNA (Qiagen) by lipofection at 1nM. Additionally, neurospheres from GSCs
expressing the GFP-miRNA constructs were dissociated and placed into single cell
suspension in each well of another 96-well plate. Finally, neurospheres from GSCs
expressing the GFP-miRNA-scramble construct (control) were dissociated and
placed into single cell suspension in each well of another 96-well plate. After 3
weeks of incubation, GSC neurospheres in all 96-well plates were quantified.
Percentage of neurosphere formation in each GSCs experimental group was
compared to that of untreated GSC controls, as well as to that of GSCs expressing
the

GFP-miRNA-scramble

construct.

All

experiments

were

performed

in

quadruplicate and statistical analysis was performed utilizing paired student’s t-test.
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Effects of Exosomal MicroRNAs on GSC Tumorigenicity
GA-MSC 262 and GA-MSC 20 were expanded to 5.0 x 107 cells in MSC
growth medium. Exosomes were isolated from conditioned medium of GA-MSC 262
and GA-MSC 20 by differential ultracentrifugation, and quantified by CD63 ELISA.
Subsequently, GSC 262 and GSC 20 were expanded to 3.0 x 10 7 cells in
preparation for pre-treatment and implantation. GSCs were then pre-treated with
either NSC medium, GA-MSC-derived exosomes (1.0 x 109 exosomes/mL), GAMSC-derived exosomes (1.0 x 109 exosomes/mL) plus anti-miR (Qiagen) by
lipofection at 1nM, and anti-miR (Qiagen) by lipofection at 1nM. Additionally, GSCs
expressing the GFP-miRNA construct, and GSCs expressing the GFP-miRNAscramble construct, we expanded to 7.5 x 106 cells each. After 96 hours of pretreatment, excess exosomes were eliminated by PBS wash, and GSC neurospheres
were dissociated. GSCs were then injected into the right frontal lobe of nude mice
(n=15/group, 5.0 x 105 cells/mouse), utilizing a cranial bolt-guided, stereotactic
system. A cohort of mice (n=9) were followed until moribund and then sacrificed.
Another cohort of mice (n=6) were sacrificed at 20 and 40 days post implantation.
After sacrifice, mouse brains were removed, embedded in paraffin, and sectioned
tumors. Tumor volumes and survival results of the GSCs treated with GA-MSCderived exosomes were compared to untreated GSC controls. Tumor volumes were
calculated by adding multiple cross-sectional areas through the tumors after H&E
staining of histologic sections. Statistical analysis was performed utilizing the paired
student’s t-test for tumor volume analysis, and log-rank test for survival analysis.
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4.2 Results
Identification of Key MicroRNA in GA-MSC-Derived Exosomes
To identify potential miRNA in MSC-derived exosomes that could be causing
the increase in GSC tumorigenicity, I first evaluated the miRNA profiles of exosomes
from BM-MSCs and four GA-MSC lines (see Chapter 2 Results). I identified a subpopulation of miRNA that were highly enriched in MSC-derived exosomes when
compared to the parental cell, with changes in expression greater than 4000
hybridization intensity (> 2 standard deviations from the mean) (Table 6). I then
calculated the expression-to-enrichment ratio (E:R ratio) for each miRNA, and
graphed the distribution of the E:R ratios (Figure 33). From one extreme of this
distribution, I identified a group of 8 miRNAs that were the most highly expressed
and highly enriched (> 3 standard deviations from the mean) in MSC-derived
exosomes when compared to the parental cells (Table 7). This cutoff correlated with
average miRNA expression levels greater than 5000 hybridization intensity.
Conversely, from the other extreme of the distribution, I identified a group of 8
miRNA that were the most highly expressed and highly enriched (> 1 standard
deviation from the mean) in the parental cells when compared to MSC-derived
exosomes (Table 7). The group of miRNA that are highly expressed and highly
enriched in the parental cells are thus relatively depleted from MSC-derived
exosomes. This level of enrichment and depletion suggests the existence of a
mechanism which targets miRNAs into, or out of, MSC-derived exosomes.
Interestingly, the nucleotide composition of both the enriched and depleted
miRNAs in GA-MSC-derived exosomes are significantly different from each other.
Specifically, the Glutamine-Cytosine to Adenine-Uracil ratio (G-C:A-U) for the group
of enriched miRNAs is 2.12:1 in pre-miRNA, and 3.20:1 in mature miRNA (Table 8).
Conversely, the G-C:U-A ratio for the group of depleted miRNAs is 0.65:1 in premiRNA, and 0.72:1 in mature miRNA (Table 8). Thus, there is significantly greater
amount of G-C nucleotides, compared to U-A nucleotides, in miRNA that are
enriched in GA-MSC-derived exosomes (p < 0.01). Furthermore, analysis of the
stem-loop miRNA sequences in both the enriched and depleted miRNA in GA-MSC114

Highly Enriched
miRNA
hsa-miR-3960
hsa-miR-6087
hsa-miR-3665
hsa-miR-6089
hsa-miR-1246
hsa-miR-6090
hsa-miR-4508
hsa-miR-4497
hsa-miR-574-5p
hsa-miR-1234-5p
hsa-miR-6125
hsa-miR-4530
hsa-miR-4505
hsa-miR-3620-5p
hsa-miR-3656
hsa-miR-4516
hsa-miR-4787-5p
hsa-miR-638
hsa-miR-4492
hsa-miR-4507
hsa-miR-574-3p
hsa-miR-1587
hsa-miR-6085

hsa-miR-4484

Expression Expression
Δ
Standard
Level
Level
Expression Deviation
Cell
Exosome
4,136
19,651
15516
7.710
2,757
15,568
12811
6.365
4,030
16,364
12334
6.128
3,903
16,163
12260
6.091
563
11,941
11377
5.652
2,398
12,200
9803
4.869
644
10,268
9624
4.780
1,994
10,837
8843
4.392
1,483
9,568
8085
4.015
1,558
9,568
8011
3.978
2,153
9,926
7773
3.860
657
8,426
7769
3.858
258
7,911
7653
3.800
268
6,373
6105
3.030
1,059
7,110
6050
3.003
2,450
8,252
5802
2.880
1,764
7,561
5797
2.877
1,686
7,482
5796
2.877
176
5,726
5550
2.755
185
5,398
5213
2.587
2,743
7,882
5139
2.550
198
5,269
5071
2.516
457
5,046
4589
2.276
868
5,069
4201
2.084

Table 6. MSC-derived exosomes contain highly enriched
miRNA. MSC-derived exosomes contain 24 miRNA with a
change in expression level from the parental cell greater than
4000 hybridization intensity (> 2.0 standard deviations from
the mean).
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MSC Exosome miRNA Expression
50

Percentile

40

30
Depleted:
miR-376c-3p
miR-9-3p
miR-103a-3p
miR-107
miR-9-5p
miR-4521
miR-4284
miR-199a-5p

20

10

Enriched:
miR-4530
miR-1587
miR-3620-5p
miR-4507
miR-4508
miR-4492
miR-4505
miR-1246

0
-6

-5

-4

-3

-2

-1
0
1
2
Standard Deviation

3

4

5

6

Figure 33. GA-MSC-derived exosomes contain highly expressed
and highly enriched miRNA. Distribution of the E:R ratio for miRNA in
MSC-derived exosomes. Exosome-enriched miRNA were both highly
expressed compared to exosome-depleted miRNA, which were both
highly expressed in the parental MSC.
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A
Enriched miRNA
hsa-miR-1246
hsa-miR-4505
hsa-miR-4492
hsa-miR-4508
hsa-miR-4507
hsa-miR-3620-5p
hsa-miR-1587
hsa-miR-4530

Expression Expression
Δ
Level
Level
Expression
Cell
Exosome
563
11,941
11377
258
7,911
7653
176
5,726
5550
644
10,268
9624
185
5,398
5213
268
6,373
6105
198
5,269
5071
657
8,426
7769

E:R ratio

Standard
Deviation

241097
234683
180857
153480
151764
144924
134920
99625

8.438
8.212
6.314
5.349
5.288
5.047
4.695
3.450

E:R ratio

Standard
Deviation

-28384
-30875
-32169
-32436
-56255
-65330
-114478
-132188

-1.063
-1.150
-1.196
-1.205
-2.045
-2.365
-4.098
-4.722

B
Depleted miRNA
hsa-miR-376c-3p
hsa-miR-9-3p
hsa-miR-103a-3p
hsa-miR-107
hsa-miR-9-5p
hsa-miR-4521
hsa-miR-4284
hsa-miR-199a-5p

Expression Expression
Δ
Level
Level
Expression
Cell
Exosome
2,130
149
-1981
1,361
57
-1304
3,450
334
-3116
3,719
383
-3337
2,994
151
-2843
966
14
-952
2,729
64
-2666
2,599
50
-2549

Table 7. MSC-derived exosomes contain enriched and depleted
miRNA. (A) MSC-derived exosomes contain 8 miRNA which are the
most highly expressed and highly enriched when compared to the
parental cell (> 3.0 standard deviations from the mean). (B) MSCderived exosomes are depleted of 8 miRNA which are the most highly
expressed and highly enriched in the parental MSC (> 1.0 standard
deviations from the mean).
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A
Enriched
miRNA
miR-1246
miR-1587
miR-3620-5p
miR-4492
miR-4505
miR-4507
miR-4508
miR-4530
Average
Std Dev
p-value

Pre-miRNA Sequence Mature miRNA Sequence
G-C %
U-A%
G-C %
U-A%
43.84
56.16
42.11
57.89
60.38
39.62
66.67
33.33
70.89
29.11
81.82
18.18
76.25
23.75
94.12
5.88
68.49
31.51
72.22
27.78
67.31
32.69
75.00
25.00
80.00
20.00
93.75
6.25
76.79
23.21
77.78
22.22
67.99
32.01
75.43
24.57
11.59
16.60
0.002
0.002

B
Depleted
miRNA
miR-9-3p
miR-9-5p
miR-103a-3p
miR-107
miR-199a-5p
miR-376c-3p
miR-4284
miR-4521
Average
Std Dev
p-value

Pre-miRNA Sequence Mature miRNA Sequence
G-C %
U-A%
G-C %
U-A%
32.91
67.09
28.57
71.43
32.91
67.09
34.78
65.22
48.72
51.28
47.83
52.17
46.91
53.09
50.00
50.00
50.70
49.30
50.00
50.00
28.79
71.21
38.10
61.90
32.53
67.47
30.43
69.57
41.67
58.33
54.55
45.45
39.39
60.61
41.78
58.22
8.87
10.00
0.005
0.027

Table 8. Exosomal miRNAs have varying nucleotide ratios.
(A) MicroRNAs enriched in GA-MSC-derived exosomes contain
significantly higher percentages of G-C nucleotides compared to
U-A nucleotides. (B) MicroRNAs depleted in GA-MSC-derived
exosomes contain significantly lower percentages of G-C
nucleotides compared to U-A nucleotides.
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derived exosomes, reveals three conserved 4 nucleotide-long sub-sequences that
are specific to each group. The combination of the sub-sequences GGCU, GGAC,
and CAGG are found in 100% of the miRNA enriched in MSC-derived exosomes,
and not found together in any of the miRNA depleted from MSC-derived exosomes
(Table 9). Conversely, the combination of the sub-sequences UGUU, UGUA, and
UGUG are found in 100% of the miRNA depleted in MSC-derived exosomes, and
are not found together in any of the miRNA enriched in MSC-derived exosomes
(Table 9). This suggests that specific nucleotide motifs, as well as certain levels of
G-C:U-A enrichment, may lead to particular miRNAs being preferentially packaged
into MSC-derived exosomes.
Verification of Exosomal MicroRNA Functionality
In order to determine whether the enriched miRNA in GA-MSC-derived
exosomes are capable of affecting gene expression in GSCs, I first identified
predicted gene targets for this group of miRNAs. Specifically, utilizing the miRTarget
2.0 database, I identified 251 unique predicted gene targets for the 7 of the 8 highly
expressed and highly enriched miRNA in MSC-derived exosomes (no predicted
gene targets for miR-4508) (Table 10).198 Conversely, utilizing the miRTarget 2.0
database, I identified 245 unique predicted gene targets for all 8 of the miRNAs that
are depleted from MSC-derived exosomes (Table 10).198 Expression levels for the
predicted gene targets in the two groups were then obtained from the gene
expression profiling performed on GSC 262 and GSC 20. The expression level of
the predicted gene targets in untreated GSCs were compared with that of GSCs
treated with GA-MSC-derived exosomes. The fold change in expression of the 251
predicted gene targets for the 7 enriched miRNA, was significantly more (p < 0.01)
than the average fold change in expression of the 245 predicted gene targets for the
8 depleted miRNA (Figure 34). These results indicate that highly expressed and
highly enriched miRNA in GA-MSC-derived exosomes are capable of downregulating their predicted gene targets in GSCs. These findings also indicate that the
predicted gene targets for depleted miRNA were not as down-regulated in GSCs
after treatment with GA-MSC-derived exosomes, due to their low expression level.
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A

Table 9. Exosomal miRNA contain specific nucleotide sequences. (A) MicroRNAs enriched in GA-MSCderived exosomes contain 3 specific nucleotide motifs (CAGG, GGAC, and GGCU) in their stem-loop sequences,
which are not present to a high degree in depleted miRNAs.
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B

Table 9. Exosomal miRNA contain specific nucleotide sequences. (B) MicroRNAs depleted in GA-MSC-derived
exosomes contain 3 specific nucleotide motifs (UGUG, UGUA, and UGUU) in their stem-loop sequences, which are not
present to a high degree in enriched miRNAs.
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Gene
Targets for
miRNAs
Enriched
in
Cell
(245)
Average
Std Dev
Max
q3
Median
q1
Min
ABCC5
ACOT7
ACTL6A
ACVR2B
ADIPOR1
AGAP1
AGFG1
ALDH8A1
ANO1
ANO3
AP1S2
AP1S3
AR
ARFRP1
ARL8B
ARMC1
ATF6
ATL2
AXIN2
BCAP29
BCL10
BICD2
BNIP3L
BTLA
C10orf47
C11orf9
C1orf21
C21orf91
C9orf150
CALB2
CAPN2
CAPZA1
CASK
CCDC50
CCNJ
CD109
CD80
CDK17
CDK6
CELSR1
CHIC1
CHMP4C
CLOCK
CNOT6L
COL4A3BP
CPEB3
CRIM1
CSDA
CTNNA1
CUL3

Fold
Change

-0.53
3.55
12.14
5.15
-1.84
-4.08
-6.32
-2.44
5.04
3.10
-2.13
-2.28
-0.67
6.34
3.92
3.99
-3.52
-2.23
-2.55
-1.23
-2.22
-2.06
-2.16
-2.70
-1.83
0.91
9.80
-2.27
-1.96
-1.92
8.01
-5.77
-4.07
-3.68
3.30
-3.63
1.20
-1.13
-1.54
1.28
-2.56
0.00
-4.01
-5.30
-1.35
-0.88
-1.63
-1.20
-3.53
-1.39
-2.78
1.08
4.30
-1.52
-1.30
-2.49
-1.25

Gene
Targets for
miRNAs
Enriched
in
Exosome
(251)
Average
Std Dev
Max
q3
Median
q1
Min
ABCG4
ABR
ACCN2
ACPP
ACSF3
ACVRL1
ADAP1
ADARB2
ADD1
ADRB3
AGL
AKNA
ANTXR2
ARHGAP1
ARHGDIA
ARL2BP
ARRB1
ASCC3
ATF1
ATOH8
ATP10B
ATP6V0A2
BCAM
BEND4
BEND6
BNIPL
BRWD1
BTBD9
C17orf103
C19orf54
C1orf144
C1orf95
C2orf71
C6orf168
CACNA1E
CACNG8
CC2D1B
CD84
CFLAR
CHRNA4
CHST6
CLCC1
CLDN19
CLIP3
CMTM3
CPLX2
CPNE5
CREBL2
CRP
CRTC1

Fold
Change

-3.79
3.48
4.43
0.67
-3.09
-10.40
-17.70
-5.92
-2.13
-4.07
-3.53
-7.94
-17.04
2.22
-2.06
-5.41
-3.10
-12.41
-3.51
-3.09
-3.18
1.01
-2.02
-7.15
-2.88
-1.55
-1.54
-2.72
-3.93
-2.67
-13.30
-3.86
-1.82
-4.44
-11.33
-3.81
-1.31
-1.95
-3.02
-3.90
-2.60
-9.51
-4.28
-2.03
-16.90
-4.27
-4.36
-3.81
-1.97
1.16
-8.90
-4.34
-8.74
-4.12
-2.59
-1.06
-4.40
8.84
-2.42
-1.86
4.27
-2.56
-2.24
9.24
-1.95
1.81
0.17
2.89
-2.03
-3.05
-0.99
-0.97
-5.26
3.32
-2.32
1.79
-1.42
-2.74
-0.20
-3.11
-1.59
2.89
-1.56
0.52
-3.29
7.51
-2.77
-0.34
-1.80
5.87
2.20
-1.91
2.01
-2.74
-2.56
-2.67
-1.58
5.69
0.80
-2.79
-2.58
-0.74
1.29
-2.45
-1.99
3.20
-2.66
CTSB
CX3CL1
DAGLA
DDX6
DENND1A
DIEXF
DNAJB14
DNAL1
DPYSL5
DYNC1I1
EEFSEC
EIF4H
EMG1
ENSA
ERBB4
ERC1
ERLIN2
EVC
FAM45A
FAM53C
FANCF
FBLIM1
FBXO11
FBXO41
FOSL2
FOXK1
FUT3
FUT6
FXN
GBP4
GFER
GIPC3
GK5
GLRB
GNAI2
GPBP1L1
GPR161
GPRIN1
GRIK3
GSG1L
H3F3B
HAS2
HCN1
HOOK3
HPSE2
IBA57
IFNAR1
IL17REL
INSIG2
IRGQ
-9.30
-4.65
-3.21
-2.76
-2.34
-2.99
-3.37
-5.85
-1.86
-2.88
-2.88
-2.11
-0.15
-9.51
-3.23
-4.82
-5.69
-1.90
-3.53
-5.19
-2.73
-5.48
-16.52
-2.11
2.71
-2.88
-17.70
-6.82
-4.21
-2.58
-1.73
-2.32
-3.91
-5.07
-2.77
-2.02
-2.48
-1.14
-3.72
4.43
-2.12
-1.43
-5.18
-2.50
-7.70
-2.28
-3.12
-1.25
-3.18
-2.87
ITPRIPL2
JHDM1D
KCNJ2
KIAA0247
KIAA0317
KIAA1328
KIAA1467
KIAA1804
KIAA1826
KIF5C
KITLG
KLF5
KLLN
LARP1
LECT1
LEP
LHFP
LRP6
LRRTM1
LYVE1
MAGI1
MAGT1
MAP3K11
MAPK1
MARCH6
MBLAC2
MCTP2
MDGA2
MED26
MTMR12
MTMR6
MYBL1
N4BP1
NAA16
NAA20
NDEL1
NEDD9
NEIL1
NF1
NID1
NOVA1
NSL1
NTNG1
NUS1
NXT2
ONECUT1
ONECUT2
OSBPL3
OTUD6B
PABPC5
-1.14
-3.35
-3.15
-3.62
-2.85
-3.64
-3.70
-2.60
-1.32
-2.98
11.91
-0.48
-3.28
-2.02
2.35
-0.65
0.59
-2.78
-2.95
-3.31
8.08
-2.31
-2.31
-0.19
-1.68
-3.82
6.00
0.00
-1.92
-2.83
-2.54
-1.66
-4.01
4.65
0.00
-2.61
1.72
-2.83
3.11
-3.28
-1.93
12.14
3.26
-1.45
-3.71
-3.16
-3.02
-0.55
-2.91
-1.19
JRK
KCNS1
KIAA0930
KIAA1045
KIAA1143
KIAA1324
KIAA1755
KLHL14
KLHL5
KLK4
KSR2
LMF1
LMLN
LPHN1
LRRIQ3
LYNX1
LZTS1
MARVELD1
MCCC2
MECP2
MEN1
MFNG
MGLL
MGRN1
MLKL
MLLT1
MLX
MPPED2
MRPS25
MS4A2
MSR1
MUT
MYOT
N4BP3
NAA60
NAT8L
NCOR1
NCS1
NDOR1
NFIC
NFIX
NKIRAS2
NPTXR
ODZ3
OLFML2A
OPRM1
OSBP2
PACS1
PACSIN1
PANK1

-3.27
-4.50
-3.95
-2.47
-1.49
-3.59
-3.69
-3.09
-9.76
0.02
-2.82
-4.07
-15.44
-4.65
-1.89
-3.72
-0.96
-4.25
1.60
-2.29
-9.94
-4.16
-13.80
-4.83
-9.05
-1.59
-2.77
-15.66
-3.34
-1.83
-1.36
-1.94
-0.46
-2.46
-4.13
-1.89
-3.18
-5.61
-6.54
-6.68
-1.97
-9.43
2.39
0.10
-0.55
-1.80
0.42
-2.70
-4.09
-4.11

PAN3
PBX3
PCDH15
PCDHAC2
PCGF2
PCGF5
PCMTD1
PCSK2
PDK4
PDLIM5
PFKM
PHC3
PHYHIPL
PLA2R1
PLIN5
PNN
PODXL
POLI
POU2F1
PPM1A
PPP1R2
PPP6R2
PRDM1
PRDM6
PRPF40A
PRTG
PTCHD3
PTPLB
QTRTD1
RAB14
RAB3B
RAB3IP
RALGAPA1
RBM24
RETSAT
RIC3
RLIM
RNASEL
SAMD5
SGMS2
SHROOM4
SIRT1
SLC12A2
SLC20A2
SLC35B3
SLC4A1
SLC4A8
SLC50A1
SNAPC3
SNRK

-3.12
9.76
0.00
-2.55
-1.50
-1.58
-3.80
0.62
-2.47
0.00
-2.23
-2.70
-2.27
2.75
-2.94
-0.14
3.06
-3.04
-2.36
7.87
-2.51
-1.74
2.09
-3.04
-2.80
-3.31
0.48
-2.72
-2.45
-3.49
-1.96
-0.03
-2.24
6.53
-2.97
0.00
-3.48
-2.97
-1.83
-6.32
-3.90
0.00
-2.55
1.51
0.60
-3.81
-3.31
10.51
3.90
-5.47

PAX5
PCDH7
PCSK6
PIGX
PLEKHG4B
PLXNA4
POTEM
PPARD
PPP1R16B
PRAF2
PSAP
PSAPL1
PSEN1
PSMA5
PTCD3
PTGIS
PTPRT
RAB11A
RAB6B
RAP1GAP2
RASA1
RASGEF1A
REEP6
RFTN2
RNFT2
RPL36A
RRP7A
RTKN2
RXRA
SALL1
SARM1
SCN3A
SDC3
SEMA6A
SEPHS1
SEPN1
SEPT6
SGOL1
SH3BP2
SHROOM3
SKIL
SLC16A7
SLC22A15
SLC28A3
SLC35E1
SLC35E2
SLC45A2
SLC46A1
SLC6A9
SLX4

-5.20
-3.22
-4.22
-2.60
-3.37
-2.15
-0.56
-15.59
-11.54
-3.02
-6.49
-0.64
-0.01
-2.09
-1.83
-2.09
-3.72
-2.80
-2.38
-3.40
-3.09
-1.92
-2.35
-4.05
-1.33
-2.43
-2.40
-2.91
-1.74
-2.87
-3.32
-1.07
-3.70
-1.04
-8.68
-3.35
-4.66
-5.84
-3.10
-1.83
-5.97
-2.99
-4.73
-4.58
-2.30
-2.40
-6.26
-4.16
-10.29
-2.06

SNX25
SNX7
SPOPL
SPTLC2
SREK1IP1
SRGAP1
STARD13
SYNJ1
TBC1D15
TCEA1
TGFB2
THUMPD3
TIAM1
TMEM120B
TMPRSS15
TNC
TNKS2
TNPO1
TNRC6B
TRIM25
TSPAN6
TTC8
UBE3C
VGLL3
VPS26A
WDR1
WNK3
YAF2
YOD1
ZAK
ZBTB41
ZCCHC2
ZFPM2
ZFR2
ZHX1
ZMYM2
ZNF20
ZNF292
ZNF440
ZNF586
ZNF664
ZNF704
ZNF763
ZNF776
ZNF814

-1.90
0.00
-2.12
-3.75
-2.82
-3.48
-4.31
-1.86
-2.81
0.77
4.29
-1.53
-2.37
-1.44
-4.31
0.68
-3.11
-0.49
7.72
-2.58
-2.48
8.99
-2.31
-1.54
-1.52
-0.22
-1.38
0.00
-2.67
-2.46
-2.23
-2.94
-1.67
2.09
4.43
4.38
5.91
-1.71
-3.70
2.40
11.53
10.10
-3.40
-3.16
-1.84

SMG7
SPOCK2
ST3GAL1
ST3GAL2
STX16
STYX
SUV39H1
SYNGAP1
SZT2
TAGLN
TLN2
TM2D2
TMC7
TMEM123
TMEM184A
TOB2
TOM1L2
TP53I11
TP73
TRMT11
TSPAN18
TSPAN9
TTYH2
TTYH3
TUSC5
TYRO3
UBR2
USP30
VAMP1
VAT1
VSX2
WDR48
WDTC1
WWP1
YY1AP1
ZBTB8A
ZC3H7B
ZCCHC24
ZDHHC8
ZFP41
ZFP90
ZMIZ2
ZNF155
ZNF267
ZNF320
ZNF37A
ZNF445
ZNF518B
ZNF594
ZZZ3

-6.13
-2.51
-3.46
-1.88
-3.66
-3.59
-2.21
-2.59
-1.95
-1.08
2.21
-2.19
-2.10
-1.94
-3.00
-3.27
-3.25
-5.87
-4.05
-2.30
-5.81
-12.31
-3.27
-2.58
-4.14
-1.00
-3.12
-1.55
-4.00
-3.28
0.93
-1.49
-3.07
-3.20
-5.39
-2.91
-0.82
-3.54
-2.88
-2.24
3.49
-3.10
-14.98
-0.64
-3.36
-3.47
-2.63
-1.43
-2.02
-2.74

Table 10. MicroRNAs enriched in GA-MSC-derived exosomes down-regulate predicted
gene targets in GSCs. Expression levels of predicted gene targets for miRNA enriched and
depleted in GA-MSC-derived exosomes.

CYLD
CYYR1
DCBLD2
DCUN1D4
DDHD2
DDX18
DICER1
DOK6
DR1
DSCC1
DTD1
E2F7
EIF2C4
EIF4E
ENAH
ENPEP
ENTPD1
ERMN
ESRRG
FAM107B
FAM115C
FAM176A
FAM91A1
FBN1
FBXW2
FGF2
FGFRL1
FIGN
FLRT3
FOXM1
FSTL1
GABARAPL2
GABRA1
GABRB2
GALNT3
GGPS1
GNPDA2
GNPNAT1
GOLPH3
GON4L
GTPBP3
HERPUD1
HIC2
HIPK2
HS6ST1
HSPA12A
IFI44
IPMK
ITGB1
ITM2B
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Figure 34. Predicted gene targets of exosome enriched
miRNA are down-regulated after treatment of GSCs with
GA-MSC-derived exosomes. Change in expression level
for predicted targets of exosome enriched miRNA, versus
that of exosome depleted miRNA, demonstrating a
significant difference (p < 0.001, Wilcoxon test) after
treatment of GSCs with GA-MSC-derived exosomes for 48
hours. The average and median fold change of predicted
targets for exosome depleted miRNA was -0.53 and -1.84,
respectively. The average and median fold change of
predicted targets for exosome enriched miRNA was -3.79
and -3.09, respectively.
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MicroRNA in GA-MSC-Derived Exosomes Increase GSC Proliferation
To determine the direct influence of the GA-MSC-derived exosome enriched
miRNA on GSC proliferation, I evaluated effects on proliferation after the overexpression of these miRNA in GSCs. Specifically, I utilized lentiviral transduction to
over-express each of the 7 enriched exosomal miRNAs that had predicted gene
targets in GSC 262 and GSC 20. Over-expression of miRNA was verified by qRTPCR analysis of RNA isolated from lentiviral transduced GSCs (Figure 35).
Importantly, increases in expression of the 7 enriched exosomal miRNA were also
seen in qRT-PCR analysis of GSCs after treatment with GA-MSC-derived exosomes
(Figure 35). Of the 7 miRNAs evaluated, only the over-expression of miR-1587 and
miR-3620-5p produced significant increases (p < 0.05) in proliferation of GSCs,
which were similar to that of GSCs after treatment with GA-MSC-derived exosomes
(Figure 36). GSC proliferation was also increased with the transduction of miR1246, however the affect was not significant (p > 0.05). Interestingly, GSC
proliferation was also increased after the transduction of the LV-GFP-miR-scramble
construct, however not to the degree of GSCs after treatment with GA-MSC-derived
exosomes. These results indicate that both miR-1587 and miR-3620-5p are capable
of increasing GSC proliferation.
MicroRNA in GA-MSC-Derived Exosomes Increase GSC Clonogenicity
To determine the direct influence of the GA-MSC-derived enriched miRNA on
GSC clonogenicity, I evaluated the effects on clonogenicity after over-expression of
these miRNA in GSCs. Specifically, I utilized lentiviral transduction to over-express
each of the 7 enriched exosomal miRNA that had predicted gene targets in GSC 262
and GSC 20. Of the 7 miRNAs evaluated, only the over-expression of miR-1587
produced a significant increase (p < 0.05) in clonogenicity of GSCs, which was
similar to that of GSCs after treatment with GA-MSC-derived exosomes (Figure 37).
GSC proliferation was also increased with the transduction of miR-3620-5p, however
the affect was not significant (p > 0.05). Interestingly GSC clonogenicity was not
affected after transduction with the LV-GFP-miR-scramble construct. These results
indicate that only miR-1587 is capable of increasing GSC clonogenicity.
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Figure 35. Lentiviral transduction of miRNA constructs increases
expression in GSCs. (A) qRT-PCR data for GSC 262 demonstrating
significant fold increases in all enriched exosomal miRNA after delivery of
GA-MSC 262-derived exosomes. (B) qRT-PCR data for GSC 262
demonstrating no significant increases in enriched exosomal miRNA after
transduction with the LV-miR-scramble construct. (C) qRT-PCR data for
GSC 262 demonstrating a significant increase in miR-1246 after
transduction with the LV-miR-1246 construct.
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Figure 35. Lentiviral transduction of miRNA constructs increases
expression in GSCs. (D) qRT-PCR data for GSC 262 demonstrating a
significant increase in miR-1587 after transduction with the LV-miR-1587
construct. (E) qRT-PCR data for GSC 262 demonstrating a significant
increase in miR-3620-5p after transduction with the LV-miR-3620-5p
construct. (F) qRT-PCR data for GSC 262 demonstrating a significant
increase in miR-4492 after transduction with the LV-miR-4492 construct.
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Figure 35. Lentiviral transduction of miRNA constructs increases
expression in GSCs. (G) qRT-PCR data for GSC 262 demonstrating a
significant increase in miR-4505 after transduction with the LV-miR-4505
construct. (H) qRT-PCR data for GSC 262 demonstrating a significant
increase in miR-4507 after transduction with the LV-miR-4507 construct.
(I) qRT-PCR data for GSC 262 demonstrating a significant increase in miR4530 after transduction with the LV-miR-4530 construct.
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Figure 35. Lentiviral transduction of miRNA constructs increases
expression in GSCs. (A) qRT-PCR data for GSC 20 demonstrating
significant fold increases in all enriched exosomal miRNA after delivery of
GA-MSC 262-derived exosomes. (B) qRT-PCR data for GSC 20
demonstrating no significant increases in enriched exosomal miRNA after
transduction with the LV-miR-scramble construct. (C) qRT-PCR data for
GSC 20 demonstrating a significant increase in miR-1246 after transduction
with the LV-miR-1246 construct.
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Figure 35. Lentiviral transduction of miRNA constructs increases
expression in GSCs. (D) qRT-PCR data for GSC 20 demonstrating a
significant increase in miR-1587 after transduction with the LV-miR-1587
construct. (E) qRT-PCR data for GSC 20 demonstrating a significant
increase in miR-3620-5p after transduction with the LV-miR-3620-5p
construct. (F) qRT-PCR data for GSC 20 demonstrating a significant
increase in miR-4492 after transduction with the LV-miR-4492 construct.
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Figure 35. Lentiviral transduction of miRNA constructs increases
expression in GSCs. (G) qRT-PCR data for GSC 20 demonstrating a
significant increase in miR-4505 after transduction with the LV-miR-4505
construct. (H) qRT-PCR data for GSC 20 demonstrating a significant
increase in miR-4507 after transduction with the LV-miR-4507 construct.
(I) qRT-PCR data for GSC 20 demonstrating a significant increase in miR4530 after transduction with the LV-miR-4530 construct.
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Figure 36. Over-expression of specific exosome enriched miRNA increases proliferation in GSCs.
(A) Proliferation assay for GSC 262 over-expressing miRNA that are enriched in GA-MSC-derived
exosomes, demonstrating a significant increase in GSC viability with the over-expression of miR-1587
and miR-3620-5p. As expected, treatment of GSC 262 with GA-MSC 262 derived exosomes, also
significantly increased viability. (B) Proliferation assay for GSC 20 over-expressing miRNA that are
enriched in GA-MSC-derived exosomes, demonstrating a significant increase in GSC viability with the
over-expression of miR-1587 and miR-3620-5p. As131
expected, treatment of GSC 20 with GA-MSC 20
derived exosomes, also significantly increased viability.
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Figure 37. Over-expression of miR-1587 in GSCs increases proliferation. (A) Proliferation assay for
GSC 262 over-expressing miR-1587, demonstrating a significant increase in GSC viability similar to that
of treatment with GA-MSC 262-derived exosomes. This increase in GSC viability was reversible with the
addition of a miR-1587 inhibitor. (B) Proliferation assay for GSC 20 over-expressing miR-1587,
demonstrating a significant increase in GSC viability similar to that of treatment with GA-MSC 20derived exosomes. This increase in GSC viability was reversible with the addition of a miR-1587
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inhibitor. .

MicroRNA-1587 in GA-MSC-Derived Exosomes Increases GSC Proliferation
To evaluate a causal role of miR-1587 in the proliferation effects produced by
GA-MSC-derived exosomes on GSCs, I conducted further proliferation assays
aimed at inhibiting miR-1587. Specifically, I treated GSCs with GA-MSC-derived
exosomes and anti-miR-1587 by lipofection, and compared results to GSCs treated
with GA-MSC-derived exosomes. As expected, the treatment of GSC with GA-MSCderived exosomes significantly increased proliferation, and was able to be partially
reversed with the addition of anti-miRNA-1587 (Figure 38). Importantly, GSC
proliferation was not affect by treatment with anti-miRNA alone. This indicates that
miR-1587 contained within GA-MSC-derived exosomes has a causal role in
increasing the proliferation of GSCs.
MicroRNA-1587 in GA-MSC-Derived Exosomes Increases GSC Clonogenicity
To evaluate a causal role of miR-1587 in the self-renewal effects produced by
GA-MSC-derived exosomes on GSCs, I conducted further clonogenicity assays
aimed at inhibiting miR-1587. Specifically, I treated GSCs with GA-MSC-derived
exosomes and anti-miR-1587 by lipofection, and compared results to GSCs treated
with GA-MSC-derived exosomes. As expected, the treatment of GSC with GA-MSCderived exosomes significantly increased clonogenicity, and was able to be partially
reversed with the addition of anti-miRNA-1587 (Figure 39). Importantly, GSC
clonogenicity was not affect by treatment with anti-miRNA alone. This indicates that
miR-1587 contained within GA-MSC-derived exosomes has a causal role in
increasing the clonogenicity of GSCs.
Verification of miR-1587 Functionality in GSCs
Given

that

miR-1587

most

significantly

increased

proliferation

and

clonogenicity in GSCs when compared to the other six highly expressed and highly
enriched exosomal miRNAs, I assessed its functionality by directly analyzing one of
its gene targets. Specifically, I focused on a major predicted target of miR-1587, the
nuclear hormone receptor co-repressor-1 (NCOR1), which had a predicted targeting
score of 90 (miRTarget 2.0 database).198 I evaluated the expression of NCOR1 in
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Figure 38. Over-expression of specific exosome enriched miRNA in GSCs increases
clonogenicity. (A) Clonogenic assay for GSC 262 over-expressing miRNA that are enriched in GAMSC-derived exosomes, demonstrating a significant increase in GSC clonogenicity with the overexpression of miR-1587. As expected, treatment of GSC 262 with GA-MSC 262 derived exosomes,
also significantly increased clonogenicity. (B) Clonogenic assay for GSC 20 over-expressing miRNA
that are enriched in GA-MSC-derived exosomes, demonstrating a significant increase in GSC
clonogenicity with the over-expression of miR-1587. 134
As expected, treatment of GSC 20 with GA-MSC
20 derived exosomes, also significantly increased clonogenicity.
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Figure 39. Over-expression of miR-1587 in GSCs increases clonogenicity. (A) Clonogenic assay for
GSC 262 over-expressing miR-1587, demonstrating a significant increase in GSC clonogenicity similar
to that of treatment with GA-MSC 262-derived exosomes. This increase in GSC clonogenicity was
reversible with the addition of a miR-1587 inhibitor. (B) Clonogenic assay for GSC 20 over-expressing
miR-1587, demonstrating a significant increase in GSC clonogenicity similar to that of treatment with
GA-MSC 20-derived exosomes. This increase in GSC clonogenicity was reversible with the addition of a
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miR-1587 inhibitor. .

untreated GSC controls, GSCs over-expressing GFP-miR-1587, GSCs treated with
GA-MSC-derived exosomes, and GSCs treated with GA-MSC-derived exosomes
plus anti-miR-1587. As expected, over-expression of miR-1587 in GSCs, and
treatment of GSCs with GA-MSC-derived exosomes, decreased the expression of
NCOR1, when compared to untreated GSC controls (Figure 40). Most importantly,
treatment of GSCs with GA-MSC-derived exosomes plus anti-mir-1587 inhibitor
partially reversed the negative regulation of NCOR1. These results indicate that
regulation of NCOR1 in GSCs by miR-1587 in GA-MSC-derived exosomes, plays a
crucial role in increasing the proliferation and clonogenicity in GSCs.
MicroRNA in GA-MSC-Derived Exosomes Increase GSC Tumorigenicity
In order to evaluate whether miR-1587 could significantly increase the
tumorigenicity of GSCs, I conducted in vivo experiments using GSC 20 overexpressing miR-1587. These experiments are currently in progress, and mice have
been injected with GSC 20 in 6 groups (n=15/group): untreated GSC 20 controls,
GSC 20 treated with GA-MSC-derived exosomes, GSC 20 treated with GA-MSCderived exosomes plus anti-miR-1587 inhibitor, GSC 20 treated with anti-miR-1587
inhibitor alone, GSC 20 over-expressing miR-1587, and GSC 20 over-expressing
miR-scramble. Of the 15 mice, 9 will be followed for survival and then euthanized,
and 6 will be sacrificed for time point comparison. I expect similar results as those
described from my in vitro experiments. GSC 20 over-expressing miR-1587 should
increase tumor burden and decrease median survival when compared to untreated
GSC 20 controls. Additionally, the increase in tumor burden and decrease in median
survival should be similar to that of GSC 20 treated with GA-MSC-derived
exosomes. Moreover, there should be a significant decrease in tumor burden and
increase in median survival between GSC 20 treated with GA-MSC-derived
exosomes plus anti-miR-1587. Lastly, there should not be a significant difference in
tumor burden or median survival when comparing untreated GSC 20 controls to
GSC 20 treated with anti-miR-1587, and to GSC 20 over-expressing miR-scramble.
Demonstration of these results would indicate that miR-1587 in GA-MSC-derived
exosomes has a causal role in increasing the tumorigenicity of GSCs.
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Figure 40. NCOR1 is down-regulated in GSCs overexpressing miR-1587. Western blot analysis of the functionality
of miR-1587 in GSC, demonstrating a baseline expression of
the predicted miR-1587 target, the nuclear receptor corepressor-1 (NCOR1) gene, in GSC controls. Expression of
NCOR1 is down-regulated with GSCs over-expressing miR1587, which is similar to that of treatment with GA-MSC-derived
exosomes. This down-regulation of NCOR1 expression is
reversible with the addition of a miR-1587 inhibitor.
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4.3 Discussion
In this chapter I show for the first time that GA-MSC-derived exosomes
contain highly expressed and highly enriched miRNA, which share conserved
nucleotide sequences. Furthermore, global analysis of the data from gene
expression profiling showed that the expression of predicted gene targets of these
miRNA was down-regulated in GSCs after treatment with GA-MSC-derived
exosomes. Of the highly expressed and highly enriched exosomal miRNA, only miR1587 was able to increase both GSC proliferation and clonogenicity in in vitro
experiments. Importantly, increased levels of miR-1587 in GSC correlated with the
down-regulation of NCOR1, a major predicted gene target of miR-1587.
The packaging of specific RNA species in exosomes is well established, and
is now recognized as an ordered, non-random, process. With respect to MSCs, the
miRNA profiles of secreted exosomes are known to be significantly different from
that of the parental cell.199-200 This difference includes certain miRNA that are either
enriched or depleted in MSC-derived exosomes.201 These studies suggest a normal
physiologic role for the process of miRNA trafficking and packaging into exosomes.
With regards to cancer, RNA that are preferentially packaged and enriched in
exosomes are being examined as diagnostic modalites. Exosomes derived from
cancer cells, termed oncosomes, are viewed as an extension of the tumor itself, and
the specific RNA profiles are being investigated in order to screen for and diagnose
many different types of cancer, including prostate, bladder, kidney, liver, colorectal,
ovarian, lung, breast, leukemia, melanoma and even brain cancers. 81,202-210
Together, these MSC and cancer studies suggest that the enrichment of RNA in
exosomes is a process that not only occurs under normal physiologic conditions, but
also in the pathologic processes of cancer.
The recognition of specific nucleotide sequences in normal physiologic cell
biology is well described. For instance, in the process of transcribing a gene,
transcription factors recognize and bind to certain core promoter regions on the DNA
strand upstream of the gene, such as the TATA-box sequence of 4-nucleotides.211
This recognition and binding is essential for subsequent binding of RNA polymerase
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and initiation of gene transcription.211 Likewise, specific 3-nucleotide-long sequences
in mRNA transcripts (codons) are then recognized and bound by complementary
sequences of tRNA carrying specific amino acids.212 This recognition is a key step in
the ribosomal translation of mRNA into a protein gene product.212 Thus, gene
expression is reliant upon effective recognition of specific nucleotide sequences.
Therefore, it is reasonable that nucleotide sequences on miRNA are recognized and
bound by proteins responsible for the trafficking of RNA into exosomes.
The process by which RNA is packaged within exosomes is not well
established, however there is evidence demonstrating that specific nucleotide
sequences may provide recognition sites for directing specific RNA species to
exosomes. Specifically, Batagov, et al., in the study of fibroblast-derived exosomes,
was the first to demonstrate that the presence of three different 8-nucleotide
sequences (ACCAGCCU, CAGUGAGC, and UAAUCCCA), present in mRNA and
pre-miRNA, directed enrichment of these RNA transcripts into exosomes.213 These
nucleotide motifs were discovered by computational analysis utilizing cluster
algorithms to identify nucleotide commonalities. Since this initial study, ColumbaCabezas and colleagues demonstrated that the Gag p17 matrix protein of HIV-1
contained a 117-nucleotide region that was essential for packing of unspliced HIV-1
mRNA into exosomes derived from infected cells.214 Without this nucleotide motif,
HIV-1 mRNA was not incorporated into exosomes, and instead was diverted into
viral partcles.214 This study highlights the role of a long nucleotide sequence that can
be recognized as a region for directing mRNA into exosomes. With respect to
gliomas, Bolukbasi and colleagues, recently demonstrated that a 25-nucleotide
sequence, with a smaller CTGCC core sequence, that was present in mRNA that
were highly enriched in exosomes derived from 2 glioblastoma cell lines. 71 Fusion of
this nucleotide motif to non-exosomal mRNA resulted in preferential packaging into
exosomes. Interestingly, enriched mRNA also contained a binding site for miR-1289
in their 3’-UTR, which served as a co-enrichment factor once bound.71 This study
further supports the theory of nucleotide pattern recognition for trafficking of RNA
species into exosomes. With regard to exosomal packaging proteins, VillarroyaBeltri, et al., demonstrated the binding of SUMO (small ubiquitin-like modifier) 139

heterogeneous nuclear ribonucleoprotein A2B1 (SUMO-hnRNPA2B1) to specific
nucleotide motifs on miRNAs.25 Specifically, SUMO-hnRNPA2B1 recognized and
bound the 4-nucleotide sequence of GGAG on miRNA. Although, SUMOlyation is
ubiquitin-like, it does not result in protein degradation. Instead SUMO-hnRNPA2B1
is targeted to exosomes, and consequently enriches miRNA that is bound to it.25
This study is the only one to describe the protein-mediated trafficking of miRNA into
exosomes. Interestingly, the GGAG miRNA motif is similar to one of the 4-nucleotide
sequences identified in my analysis of highly expressed and highly enriched miRNAs
in MSC-derived exosomes (GGAC). Therefore it is reasonable that specific
nucleotide sequences of miRNA, combined with GC:UA enrichment, can direct the
preferential packaging of miRNA into MSC-derived exosomes.
The capability of exosomal miRNA to regulate gene expression in recipient
cells has been established in various tissues. With regards to the brain, this process
has been described in both physiologic and pathologic conditions. Specifically,
Morel, et al., demonstrated that exosomes derived from neurons can affect the
expression of amino acid transporters in astrocytes.215 The delivery of miR-124a via
neuron-derived exosomes, increased the expression of glutamate transporter-1
(GLT1) in recipient astrocytes. Furthermore, the disruption of this communication
pathway is linked to key changes that occur during the progression of amyotrophic
lateral sclerosis (ALS).215 More relevant to my work, Li at colleagues, demonstrated
that exosomes derived from the U251 glioblastoma cell line are able to alter the
transcriptome of recipient human brain microvascular endothelial cells (hBMVECs).72
The communication of exosomal miRNA significantly down-regulated the expression
of 19 genes involved in the maintenance of the blood-brain barrier.72 Together, these
two studies indicate that cells can utilize exosome-mediated regulation of gene
expression to modify the surrounding microenvironment.
Similar to the designation of genes that inhibits malignant growth as a tumorsuppressors, there are miRNAs that also inhibit malignant growth and are termed
tumor-suppressor-miRNAs.216 Specifically, the group of miRNA that were highly
expressed and highly enriched in GA-MSCs, and thus depleted from GA-MSC140

derived exosomes, consists of miRNAs that have been shown to have tumorsuppressor capabilities (Table 7). For example, Tan, et al., demonstrated that miR-9
inhibits the proliferation of gliomas cells through the down-regulation of the proproliferative cyclic-AMP element binding protein (CREB).217 Additionally, Moncini
and colleagues, demonstrate that miR-103a has a negative effect on cell growth and
migration through the down-regulation of cyclin dependent kinas-5R1 (CDK5R1).218
Similarly, Chen, et al., described the glioma-suppressing role of miR-107, which was
linked to the down-regulation of cyclin dependent kinase-2 (CDK2) and neurogenic
locus notch homolog protein-2 (NOTCH2).219 Furthermore, Gu and colleagues
demonstrated that miR-199a functions as a tumor-suppressor in gliomas by downregulating the expression of musculoaponeurotic fibrosarcoma oncogene homolog-B
(MAFB).220 Lastly, Skalsky, et al., demonstrated that miR-376c is highly expressed in
normal brain tissue and functions to down-regulate the activin receptor-like kinase-7
(ALK7) in glioblastoma.221 Each of these studies highlight the relative low expression
of these tumor-suppressor miRNAs in gliomas. These reports suggest GA-MSCs
have a repertoire of miRNA that can inhibit glioma growth and invasion, yet do not
package these tumor-suppressive miRNA into exosomes. Therefore, it is also
reasonable that oncogenic miRNAs are instead enriched in GA-MSC-derived
exosomes. The group of enriched miRNA, however have only recently been
discovered and consequently are not as well characterized as the depleted miRNAs.
Similar to the designation of genes that promote malignant growth as
oncogenes, there are miRNAs that also promote malignant growth and are termed
onco-miRNAs. However, unlike the group of depleted miRNA from MSC-derived
exosomes that are tumor-suppressive, the group of highly expressed and highly
enriched miRNA in MSC-derived exosomes consists of newly identified miRNA that
have not yet been study, and consequently have no known function. The potential
for these unstudied miRNA to be onco-miRNAs is suggested by my experimental
results in which MSC-derived exosomes increased the tumorigenicity of GSCs.
Given the wide range of genes that one miRNA can target, and the similarly wide
range of miRNA that can target one gene, the effects of GA-MSC-derived exosomal
miRNA on GSCs are most likely not attributable to a single miRNA. However, my
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results indicate that miR-1587 is not only highly expressed and highly enriched in
MSC-derived exosomes, but is at least one exosomal miRNA that appears to
mediate the increase in proliferation and clonogenicity of GSCs. My study is also the
first to describe the targeting and down-regulation of the nuclear receptor corepressor-1 (NCOR1) in gliomas by miR-1587. NCOR1 was first identified and
characterized by Horlein and colleagues in 1995.222 In this study, researchers
discovered a transcriptional co-regulatory protein that could repress expression of
gene targets for thyroid hormone receptors and retinoic acid receptors, independent
of ligand binding. Since the discovery of NCOR1, several other NCORs have been
identified, and have been shown to function in both normal physiologic and
pathologic conditions, including cancer.223-225
The association of NCOR1 with thyroid hormone receptors and retinoic acid
receptors suggested a role in both thyroid cancer and retinoblastoma.226-227 Initially
in 2007, Furuya, et al., demonstrated that a loss of function, or lower cellular
expression, of NCOR1 resulted in increased proliferation and motility of thyroid
tumor cells.226 These effects resulted from decreased NCOR1-mediated repression
of PI3K/AKT signaling, leading to a more aggressive follicular thyroid carcinoma
phenotype.226 This was the first report linking NCOR1 function to thyroid cancer, and
it’s designation as a tumor-suppressor gene in this type of hormone-related cancer.
Recently in 2013, Nazha and colleagues, demonstrated that low expression of
NCOR1 in the nucleus of retinoblastoma cells increased their proliferation and
promoted the maintenance of an undifferentiated state.227 This expression pattern
was also demonstrated in retina-progenitor cells, which supports the role of NCOR1
as a regulator of cellular differentiation. This study was the first to describe a tumorsuppressor role for NCOR1 in retinoblastoma, and revealed the cellular localization
of NCOR1 to be key to its function.227
In gliomas, NCOR1 was originally thought to be an oncogene, but recent
studies have suggested a tumor suppressor role. A study published by Park and
colleagues in 2007, initially established an oncogenic function for NCOR.228
Outcomes from this study highlighted the tumor-promoting effects resulting from high
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expression levels of NCOR in gliomas. These effects were linked to the
phosphorylation and subsequent shuttling of NCOR out of the nucleus and into the
cytoplasm. Thus, elevated nuclear expression of NCOR was associated with
maintenance of an undifferentiated state, and deemed oncogenic in gliomas. 228
However, these researchers were evaluating the NCOR family in the U87
glioblastoma cell line, and did not distinguish between effects caused by NCOR1
and NCOR2. Although both co-repressors associate with the same hormone
receptors, their relative expression levels in the cytoplasm and nucleus are quite
different, as demonstrated by Campos, et al., in 2010. 229 Results from this study
demonstrated a low expression of NCOR1 in both cytoplasmic and nuclear fractions,
and high nuclear expression of NCOR2, in tumor cells extracted from 283 patients
with varying grades of astrocytic gliomas. This study suggests that NCOR2 may
have an oncogenic function, while NCOR1 has a tumor-suppressor function.229
Consistent with this concept, in 2013, Heldring, et al., also demonstrated the tumorsuppressor function of NCOR1 in gliomas, by showing that the knockdown of
NCOR1 resulted in glioma growth and invasiveness both in vitro and in vivo.230
Furthermore, decreased expression of NCOR1 correlated with the epithelial-tomesenchymal transition in glioblastoma.230 Together, these studies indicate that
down-regulation of the tumor-suppressor NCOR1 in gliomas, results in the
promotion of growth and evolution of the malignancy. Therefore, my experimental
result demonstrating an increase in GSC proliferation and clonogenicity caused by
miR-1587-mediated down-regulation of NCOR1 is consistent with the literature.
My future experiments include linking NCOR1, and thus miR-1587, to the
increases in GSC tumorigenicity demonstrated in my results. This would involve the
use of siRNA to knockdown expression of the NCOR1 gene in GSCs, simulating the
effect of miR-1587 in GA-MSC-derived exosomes. Silencing of NCOR1 with shRNA
eliminates the non-specific effects that miR-1587 could induce by the downregulation of other genes in addition to NCOR1. Given the results from Heldring, et
al., I expect to find an increase in GSC tumorigenicity when NCOR1 expression is
suppressed. This result would mirror that of miR-1587 over-expression in GSCs, and
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GSCs treated with GA-MSC-derived exosomes, thus defining a final biological
pathway by which GA-MSC-derived exosomes promote gliomas.
One of the weaknesses of my study was the further evaluation of only one
miRNA based on the results from my in vitro experiments. Specifically, I did not
perform western blot analysis or in vivo studies of miR-3620-5p, which significantly
increased the proliferation of GSCs, but did not have a significant effect on GSC
clonogenicity. Additionally, I also did not perform further analysis on miR-1246 which
increased both GSC proliferation and clonogenicity, but not to a significant degree.
Further investigation of the predicted gene targets of these two miRNA, combined
with in vivo studies, may indicate a synergistic tumor-promoting function with miR1587. Another weakness in this study was the evaluation of only one predicted gene
target of miR-1587. Although identification of putative miR-1587 targets has not yet
been described, verification of its functionality by demonstrating the down-regulation
of another predicted gene target would better support my in vitro results, classifying
miR-1587 as an onco-miRNA in MSC-derived exosomes.
Conversely, a strength of this study was the utilization of computational
analysis of the miRNA profiles of BM-MSC-derived and four GA-MSC-derived
exosomes in order to develop a list of potential oncogenic miRNAs. This process
was significantly more efficient that a shotgun approach analyzing all miRNA in
MSC-derived exosomes to identify those which are tumor-promoting. Another
strength of this study was the use of gene expression profiling to demonstrate the
down-regulation of predicted gene targets for enriched miRNA, after treatment of
GSCs with GA-MSC-derived exosomes. This method ensured that the group of
potential oncogenic exosomal miRNA had a significant effect on the GSC
transcriptome before conducting in vitro and in vivo experiments. A final strength of
this study was utilization of an anti-miR-1587 inhibitor to reverse the effects of GAMSC-derived exosomes on GSCs in my in vitro experiments. This treatment group
helped isolate the effects of miR-1587, and ensured that no other exosomal miRNAs
were responsible for the increases seen in GSC proliferation and clonogenicity.

144

4.4 Conclusions
My experimental results demonstrate that GA-MSC-derived exosomes are
enriched with a specific group of miRNA, as compared to GA-MSCs. Interestingly,
these enriched miRNA contained specific nucleotide motifs that were common
among the group, and absent from depleted miRNA. Furthermore, the expression of
predicted gene targets for the enriched miRNAs, were significantly decreased in
GSCs after treatment with GA-MSC-derived exosomes. Importantly, the overexpression of one of the enriched miRNAs (miR-1587) significantly increased both
proliferation and clonogenicity in GSCs. Finally, a predicted gene targets for this
specifically enriched miRNA (NCOR1), was decreased after miR-1587 overexpression in GSCs and after treatment of GSCs with GA-MSC-derived exosomes.
These results indicate that the mechanism by which GA-MSC-derived exosomes
promote glioma growth is through the delivery of specific oncogenic miRNA to
recipient GSCs.
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Chapter V
Research Summary
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Research Summary

For my thesis work, I hypothesized that GA-MSC-derived exosomes enhance
the growth and evolution of gliomas. My initial experiments studied the production
system of GA-MSC-derived exosomes and subsequently characterized their
proteomic and genomic contents. I then investigated the interaction between GAMSC-derived exosomes and GSCs, and showed that GA-MSC-derived exosomes
increases in the tumorigenicity of GSCs. Finally, I discovered a link between a
specific miRNA (miR-1587), delivered in GA-MSC-derived exosomes to GSCs, that
was

responsible

for

the

glioma-promoting

properties

of

this

intercellular

communication pathway. This system culminated in the down-regulation of a tumorsuppressor protein in gliomas (NCOR1), and revealed the onco-potentiating ability of
GA-MSC-derived exosomes. These results validate my hypothesis and show for the
first time that stroma-derived exosomes in the glioma microenvironment can
influence growth and evolution of the malignancy via the delivery of specific miRNA
to recipient GSCs.
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5.1 Experimental Conclusions
These experimental results are the first to demonstrate the production of
characteristic exosomes by GA-MSCs. Moreover, the production of GA-MSCderived exosomes varies with exposure to different levels of cellular stressors.
Additionally, GA-MSC-derived exosomes do not contain major proteins or cytokines.
However, GA-MSC-derived exosomes do contain numerous miRNA with distinct
profiles compared to parental MSCs. Indeed, a specific group of miRNAs are highly
expressed in GA-MSC-derived exosomes. These results prove that GA-MSCs are
capable of producing exosomes whose content have the potential to impact the
biology of recipient cells.
By tracking GA-MSC-derived exosomes utilizing a GFP-CD63 fusion protein, I
showed that GSCs can internalize GA-MSC-derived exosomes. More importantly, I
demonstrate for the first time that GA-MSC-derived exosomes significantly increase
the proliferation and clonogenicity of GSCs in vitro. Moreover, GA-MSC-derived
exosomes can significantly increase the tumorigenicity of GSCs in vivo.
Furthermore, pre-treatment of GSCs with GA-MSC-derived exosomes increases
tumor burden and decrease median survival. These results prove that GA-MSCderived exosomes can interact with GSCs to influence their biology.
My experimental results demonstrate that GA-MSC-derived exosomes are
enriched with specific miRNAs, as compared with parental GA-MSCs. Interestingly,
enriched miRNAs contained specific nucleotide motifs that were common among the
group. Furthermore, the expression of predicted gene targets for the enriched
miRNAs was significantly decreased in GSCs after treatment with GA-MSC-derived
exosomes. Importantly, the over-expression of one of the enriched miRNAs (miR1587) increased both proliferation and clonogenicity in GSCs. Finally, one of the
predicted gene targets for this specifically enriched miRNA (NCOR1), was
decreased with both miRNA over-expression in GSCs and GSCs treated with GAMSC-derived exosomes. These results indicate that an enriched miRNA in GAMSC-derived exosomes alters the expression of a tumor-suppressor in gliomas
leading to increased glioma growth.
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5.2 Research Significance
The significance of my thesis work is far-reaching, from demonstrating
exosomal communication in the tumor microenvironment to describing selective
miRNA packaging, to reporting the loss of tumor-suppressor activity in gliomas.
These results describe several aspects of cellular biology that have never before
been shown in gliomas. Moreover, my results demonstrate the impact of the glioma
microenvironment on tumor growth, which can potentially be targeted by adjunct
therapy in the future.
The results of my studies elucidated the role of exosomal communication in
the tumor microenvironment. My results indicates that exosomes from the
microenvironment contribute to maintaining a supportive niche for malignant growth
and suggest that this mode of interaction between the tumor stroma and the tumor
propagating cells may be consistent throughout all solid tumor cancer types.
Therefore one of the major impacts of my work is the necessity to consider the
influence of tumor stroma-derived exosomes in glioma growth and future therapeutic
strategies to inhibit this tumor-supporting property.
My project also described the packaging of selective miRNA into GA-MSCderived exosomes. My results suggest that incorporation of certain materials into
exosomes is cell-of-origin specific, and may be influenced by interactions with
neighboring cells. Additionally, the packing of specific exosomal miRNA suggests
that a particular effect can be induced in recipient cells. Therefore, another major
impact from my work is the gene-altering capabilities of tumor stroma-derived
exosomes which must be taken into account in the process of glioma progression.
Lastly, my research demonstrated the specific down-regulation of a tumor
suppressor gene in glioma via delivery of GA-MSC-derived exosomes. Therefore, a
final major impact from my work is that the tumor stroma provides a nurturing
environment by regulating gene expression in tumor propagating cells, which must
be taken into account during the treatment of aggressive gliomas.
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5.3 Future Investigations
The intercellular exosomal communication between GA-MSCs and GSCs is
only one pathway in a complex network of interactions between cells within the
glioma microenvironment. In the future, I plan to expand my investigations of the
tumor niche to include evaluating the role of GSC-derived exosomes in modulation
of the surrounding stroma. Specifically, I will examine the effects of GSC-derived
exosomes on GA-MSCs, brain microvascular endothelial cells (BMVEC), astrocytes
and microglia. Given the function of these cells, this communication network may
serve to transform the microenvironment to better promote glioma growth. Thus,
GSC-derived exosomes may play a role in the recruitment of MSCs from the bone
marrow, breakdown of the blood-brain barrier, invasion into brain parenchyma, and
immunosuppression within the tumor. As an extension of this study, I would also
investigate the diagnostic and prognostic applications of GSC-derived exosomes in
serum. Some of these processes have been demonstrated in other cancer types,
and their description in gliomas is necessary.
Another direction that I would like to explore is the nucleotide motifs in miRNA
that may target them for enrichment into exosomes. Although this study is not
necessarily associated with gliomas, or cancer, it has a much broader scope for
defining the process of exosomal miRNA packaging. This investigation would involve
identifying conserved nucleotide sequences present in enriched miRNA from
exosomes from a variety of cell types. Extensive computational and cluster analysis
would be necessary for an effective and efficient approach to this experimentation.
Once key motifs were identified, artificial mutations in these sequences should result
in the decreases expression of previously enriched miRNA in exosomes.
Additionally, encoding of these sequences in previously exosome depleted miRNA,
should result in their enrichment into exosomes. Positive results of this study would
have a broad range of applications, including cancer therapy and diagnostics.
New functions of exosomes are constantly being described, and my results
combined with those of future studies will aid in the full understanding of this novel
paracrine signaling mechanism.
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